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Summary  
 
The importance of metalloenzymes in nature is reflected by their involvement in many 
fundamental processes (e.g. photosynthesis, respiration, nitrogen fixation). The creation 
of artificial metalloenzymes for chemical and biochemical applications is an intriguing 
and potentially highly rewarding area of research. As a starting point, a catalytically 
active transition metal complex or catalyst precursor needs to be incorporated into a 
host protein thereby generating a hybrid, which exhibits attractive features of 
biocatalyst and chemocatalyst. Exploiting the biotin (strept)avidin technology for the 
creation of artificial metalloenzymes, is a convenient means, to ensure the cofactor 
localisation thanks to the high affinity of biotin for streptavidin. Synthetic cofactor and 
protein host can be separately modified by chemical- and genetic means, respectively 
and subsequently combined. The topic of this thesis is to create artificial transfer 
hydrogenases relying on this technology and to study the resulting constructs. With 
the ultimate goal of implementing efficient directed evolution protocols for the 
optimization of artificial metalloenzymes and for their application in vivo, the 
interaction between the active catalyst and the biological environment needs to be 
evaluated. Mutual inhibition between the synthetic catalyst and enzymes (other than 
Sav) was identified as one potential problem. After reviewing the main organometallic-
based methods for the non-enzymatic regeneration of NADH, a solution for the 
frequently observed inhibition between the organometallic NADH regeneration system 
and the NADH dependent enzyme, namely the compartmentalization of the synthetic 
cofactor in Sav, will be discussed.  The incorporation of the active organometallic 
catalyst [Cp*Ir(biot-p-L)Cl] into streptavidin, led to an active ATHase (Artificial 
Transfer Hydrogenase), utilized for NADH regeneration, which was subsequently 
successfully  coupled in a cascade biocatalysis reaction with HbpA (a NADH and 
FADH2 dependent monooxygenase), for the selective hydroxylation of 2-
hydroxybiphenyl to 2,3-hydroxybiphenyl. Next, the stereoselectivity of the ATHase 
vi 
 
mediated-NAD+ reduction with deuterated formate as a deuteride source was 
investigated resulting in up to 90% de.  
Finally chemical variants of IrCp*/Sav- or RhCp*/Sav-based transfer hydrogenases were 
studied. In order to rapidly generate chemical diversity, a new approach for the 
creation of biotinylated complexes is presented. Tethering the biotin anchor to the Cp* 
moiety of the organometallic complex, thereby leaving three coordination sites vacant, 
enabled fast screening of libraries of bidentate ligands, which led to the identification 
α-amino amides as promising ligands for the asymmetric reduction of cyclic imines. 
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Chapter 1 
_______________________ 
Introduction 
 
1.1 Generalities about catalysis 
Enzymes are widely applied for chemical transformations[1] due to their high activity 
and selectivity resulting from their complex and well organized three-dimensional 
structure. Enzymes are able to perform complicated transformations such as 
photosynthesis, nitrogen fixation, respiration etc. Nowadays, the use of enzymes in 
industry is extensive for the synthesis of complex molecule e.g. in the production of 
pharmaceuticals, agrochemicals and flavours.[2,3] The preparation of enantiopure 
compounds from a racemic mixture or prochiral compounds is still considered  
challenging for a range of transformations. 
In 1893, Lord Kelvin was the first to define chirality “I call any geometrical figure, or 
group of points, chiral, and say it has chirality, if its image in a plane mirror, ideally 
realized, cannot be brought to coincide with itself ”.[4] Chirality is present in nature 
almost everywhere, and in different types of molecules including DNA, carbohydrates, 
amino acids, vitamins and alkaloids. Chiral molecules have two enantiomeric forms, 
which correspond to the respective image or mirror image of the molecule. Pure 
enantiomers possess the same physical and chemical properties (e.g. boiling points, 
density, solubility, redox potential, pKa, etc.) but interact differently with chiral system 
(e.g. proteins) and with polarized light (Figure 1.1).[5–7]  
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Figure 1.1 ― Some examples of the effects of enantiomers on biological systems. The central line 
indicates a mirror plane 
These few examples highlight the importance of chirality, and the importance to 
generate or isolate single enantiomers. In the context of synthesis, enantioselective 
catalysis occupies a place of choice. Its aim is to favour the exclusive formation of a 
single enantiomer starting from a racemic or prochiral starting materials. A common 
term to describe the ratio between two enantiomers, is the enantiomeric excess (ee) 
which is defined as (equation 1.1): 
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(1.1) 
 
The determination of ee can be achieved with different techniques like polarimetry, 
NMR-spectroscopy (after derivatization) and chromatographic methods (HPLC or GC). 
Commonly three different types of enantioselective catalysis are distinguished: 
heterogeneous, homogeneous and bio-catalysis. The last two research fields have 
generated a wide variety of methods for the synthesis of enantiopure compounds.[1,8]  
In homogeneous transition metal catalysis, the enantioselectivity of the reaction is 
provided by a catalyst consisting of a metal and a small enantiopure ligand directly 
bound to the metal. The chiral induction for the reaction relies on first coordination 
sphere interactions between ligand, metal and substrate, respectively. An exact 
prediction of the stereochemical outcome is difficult, and a screening approach is 
generally used.[9] In biocatalysis the chiral environment of the reaction is typically 
more precisely controlled through additional interactions of the substrate with the 
protein scaffold (hydrogen bonding, hydrophobic interactions) by the so-called “second 
coordination sphere”.[10] These additional interactions contribute to the stabilization of 
the transition state. Homogeneous catalysis and biocatalysis are complementary in 
many aspects (Table 1.1).[8,11]  
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Table 1.1 Comparison of typical features of homogeneous and enzymatic catalysis. 
 Homogeneous 
catalysis 
Bio- 
catalysis  
Substrate scope large small 
Enantiomers both enantiomers single enantiomers 
Turnover number limited large 
Metal involved any metal limited (biorelevant) 
Reaction repertoire large  small 
Reaction medium mostly organic mostly aqueous  
Optimization  chemical  genetic  
Second coordination sphere poorly defined well defined 
 
In line with arguments listen in the table above, biocatalysts can be very active and 
selective for specific reactions, whereas homogeneous catalysis covers a broader range 
of reactions. Hence, a catalytic system, which would combine the best aspects of these 
two approaches, is of high interest.  
 
1.2 Artificial metalloenzymes 
The first use of the word “enzyme” dates back to 1876 when German physiologist 
Wihelm Kühne identified it as a non-living substance able to perform fermentation.[12] 
Enzymes are macromolecules, mostly of proteinic nature, that function as bio-catalysts 
by increasing the reaction rates[13] and conform accordingly with the definition of a 
catalyst, which is ”a substance that increases the rate of a chemical reaction without 
itself being consumed”.[14]  
Metals are essential for all living organisms. They are frequently integrated in proteins 
where they contribute to structure and also often display catalytic function (such as 
photosynthesis, respiration, oxygen transport) in so-called metalloproteines.[15,16]  
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Metals play a key role in enzymes.[17] In metalloenzymes, the catalytic metal centre 
constitutes together with the coordinated moiety of the protein the 1st coordination 
sphere. The surrounding protein framework, around the 1st coordination sphere, 
constitutes the 2nd coordination sphere and plays a critical role in catalysis. 
The term “Artificial Metalloenzymes” refers to a catalyst resulting from the 
incorporation of a catalytically active metal ion or complex into a biomolecular host, 
such as a protein[11,18–20] or DNA.[21,22] 
In the light of the complementarity between homogeneous and enzymatic catalysis, 
artificial metalloenzymes appear as a promising alternative as they may combine the 
best of both worlds.[23] Artificial metalloenzymes have been successfully applied for a 
range of chemical reactions.[24–26]  
An artificial metalloenzyme consists of four elements; the biomolecular host, the 
anchor, the spacer, and the catalytic metal centre (Figure 1.2). 
 
Figure 1.2 ― Schematic representation of an artificial metalloenzyme. Chemical optimization is 
accomplished by modifying the spacer, the metal M, or the ligand scaffold X; genetic optimization is 
accomplished by site-directed mutagenesis in the proximity of the catalytic centre (*). 
There are two possible approaches to create an artificial metalloenzyme: a) de novo 
design, where the catalytic centre is incorporated into a designed polypeptide 
sequence;[27,28] b) modification of an existing protein.[23] 
The creation of artificial metalloenzymes needs to take three important parameters into 
consideration: 
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1. The choice of transition metal catalyst, which is determined by the reaction to 
be investigated.[23,29] The catalyst needs to be compatible with biomolecular 
scaffolds, and to operate under aqueous conditions. 
2. The biomolecular scaffold, which can be a polypeptide, a protein or a 
polynucleotide (RNA or DNA).[24] Apart from structural considerations, pH, 
temperature stability, and tolerance of the scaffold against organic solvents 
needs to be taken into account.[23] So far oxidations and reductions have only 
been carried out in combination with protein scaffolds, but not with DNA[23,24] 
The biomolecular scaffold affects not only the selectivity of the metal cofactor, 
but can also alter the reaction rate.[30,31] 
3. The anchoring strategy for the localization of the metal moiety in the 
biomolecular scaffold. Three different strategies are commonly distinguished: 
dative anchoring, covalent anchoring and supramolecular anchoring (Figure 
1.3). 
a. Dative anchoring relies on a metal that is linked to the biomolecular 
scaffold through a coordinative interaction of one or multiple amino acid 
side chains present in the host protein. These coordinating groups of the 
side chain typically stem from histidine, cysteine, methionine, glutamate 
or aspartate;[24] 
b. Covalent anchoring relies on the presence of a suitable electrophile in 
the ligand moiety, which reacts with accessible cysteine serine histidine 
residues.[24,29] The first example of a covalently protein linked metal 
catalyst was reported by Kaiser; [32,33]  
c. Supramolecular anchoring refers to a strong and specific non-covalent 
interaction between the biomolecular scaffolds and a small molecule 
ligand, which carries the artificial metal cofactor.[23,24,29] Whitesides was 
the first to report the creation of an artificial metalloenzyme by 
exploiting the high affinity of biotin for avidin.[34]  
 
7 
 
 
Figure 1.3 ― Different anchoring strategies: a) dative anchoring; b) covalent anchoring; c) 
supramolecular anchoring. M = catalytically active metal centre; the first coordination sphere is 
highlighted in red; the biomolecular scaffold is schematically depicted in green. 
All three different methodologies present distinct advantages and disadvantages. Dative 
anchoring does not require a chemical step to establish the linkage to the protein, but 
often suffers from selectivity due to competing coordinating residues on the surface of 
the protein. Covalent anchoring requires the presence of a unique reactive residue in 
the host protein for highly selective localization of the metal cofactor. Supramolecular 
anchoring is achieved by chemical modification of the complex with the ligand which 
binds to the protein. In principle, any cofactor which can be derivatized with a ligand 
that displays high affinity for a given protein can be employed, but the choice of 
scaffolds is accordingly limited to proteins that contain a binding pocket where the 
modified molecule can bind.[35]  
The creation of artificial metalloenzymes based on the biotin streptavidin technology is 
a well-established approach.[20,23–25,36] This technology is based on the strong 
supramolecular interaction between the host protein streptavidin and the guest 
molecule biotin (vitamin H). Streptavidin is a homotetrameric protein and each 
monomer constitutes a β-barrel which can bind a single molecule of biotin in a deep 
binding pocket leading to unambiguous positioning of the biotin ligand. The affinity of 
biotin for streptavidin  is one of the strongest non-covalent interactions known in 
nature (Ka ≈ 1013 M-1).[37,38] The introduction of the active catalyst moiety into 
streptavidin is achieved by derivatization of the valeric acid side chain of the biotin 
anchor. This derivatization does typically not alter the biotin streptavidin affinity 
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dramatically.[39]  Streptavidin is stable under harsh conditions such as pH values as low 
as 1.5, temperature (> 90°C), organic solvents (50% ethanol) and the presence of 
surfactants like sodium dodecyl sulphate.[40,41] Streptavidin can be easily expressed in E. 
coli (about 200 mg/L). Furthermore, the protein and cofactor can be modified 
independently by genetic and chemical means. These characteristics enable the 
application of artificial metalloenzymes in a wide range of catalytic transformations. 
Wilson and Whitesides were the first to use the biotin avidin technology for artificial 
metalloenzymes and incorporated a rhodium diphosphine catalyst for the asymmetric 
hydrogenation of activated olefins in avidin.[34] Following this pioneering work, many 
other catalysts have been incorporated into the structurally related streptavidin and a 
range of catalytic reactions scrutinized such as hydrogenation,[42] olefin metathesis,[43] 
transfer hydrogenation of ketones, imines and enones,[44,45] sulfoxidation,[46] 
dihydroxylation,[47] allylic alkylation [48] and C-H activation.[31]  
To evaluate the performance of artificial metalloenzymes in terms of rate, the kinetic 
model of Michaelis and Menten is typically applied (equation 1.2). In the first, step the 
enzyme (E) and the substrate (S) form a complex (ES), (k1 indicates the association rate 
and k-1 indicates the dissociation rate of the ES complex). In the second step, the 
reaction takes place and the ES complex is converted into product (P) and free enzyme 
(k2 is the rate constant for this step). The KM equals the dissociation constant of the 
enzyme substrate complex, if k2<<k-1.[49] 
 
(1.2) 
 
Another assumption is the “steady state” approximation: when the concentration of the 
substrate is much higher than the concentration of the enzyme ([S]>>[E]]), then the 
concentration of the enzyme-substrate complex ([ES]) remains constant in the initial 
phase of the reaction and the Michaelis–Menten equation can be expressed as (equation 
1.3): 
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(1.3) 
 
In the equation above, it is also assumed that the binding step is fast, thus k2 equals the 
total catalytic constant kcat which is defined as (equation 1.4): 
 
 (1.4) 
  
where [E]0 is the total enzyme concentration. The concentration of the substrate at 
which v=½Vmax is the KM. In an optimal case for catalysis, an enzyme shows high 
specific activity and should show minimal substrate (or other) inhibition.  
 
1.3 Catalytic scope 
1.3.1 NADH regeneration 
The application of biocatalysis in industrial processes has received increasing 
consideration.[50–53] Oxidoreductases present considerable potential and a large 
application field, due to their high activity and selectivity.[54,55] For their biological 
function, oxidoreductases require redox equivalents often provided in the form of 
cofactors, such as nicotinamide adenine dinucleotide (NAD+) or nicotinamide adenine 
dinucleotide phosphate (NADP+) (Figure 1.4).  
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Figure 1.4 ― NAD(P): structure and redox chemistry 
The regeneration of the cofactor is an important topic in biocatalysis, because the 
stoichiometric use of NAD(P) is not feasible due to its high cost (Table 1.2). A catalytic 
amount of cofactor is generally used in NAD(P) or NAD(P)H dependent 
biotransformations and a concurrent reaction is performed to regenerate the cofactor. 
Table 2.2 Cost of cofactors from Alfa-Aesar. Product purity: a) 97%; b) 98%; (April 2015) 
Cofactor €/g 
a) NAD+  34 
b) NADH 48 
b) NAD(P)+ 361 
b) NAD(P)H 1050 
  
Different strategies are employed for cofactor regeneration: a) the use of whole cells, 
which provide their own redox equivalents; b) the addition of a sacrificial co-substrate; 
c) the addition of a second enzyme and a co-substrate[54,56] The most  commonly 
employed enzymatic regeneration systems for synthetic applications are formate 
dehydrogenase/formic acid, glucose dehydrogenase/glucose, alcohol 
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dehydrogenase/sacrificial alcohol or glutamate dehydrogenase/glutamate.[56–58] In 
extension to the enzymatic methods mentioned above, further non-enzymatic 
regeneration approaches, namely chemical, electrochemical, and photochemical 
regeneration methods have been investigated.[59–62] Nowadays, none of the non-
enzymatic regeneration methods has reached the efficiency provided by enzymatic 
systems. Non-enzymatic regeneration methods will be discussed in chapter two of this 
thesis and include the use of artificial metalloenzymes based on the biotin 
(strept)avidin technology. The employment of artificial metalloenzymes for NADH 
regeneration will be presented in chapter 3. 
 
1.3.2 Transfer hydrogenation: asymmetric imine reduction 
The synthesis of enantiopure amines is of high interest due to the high value of these 
compounds arising from various applications in the pharmaceutical, agrochemical, and 
fine chemical industries.[63,64] Imine reduction is a convenient route to enantioenriched 
amines it has received increasing attention in the last 30 years.[65] A prominent role 
among the reduction methods is held by the asymmetric transfer hydrogenation (ATH) 
to access such compounds. ATH is an efficacious strategy to reduce ketones or imines 
with the assistance of homogeneous transition metal catalysis and an alternative to 
hydrogenation processes (using hazardous H2).[66–68] 
The first example of asymmetric transfer hydrogenation for the reduction of prochiral 
ketones or dehydrogenation of chiral alcohols, was reported in the late 1970s from 
Sinou[69] and Ohkubo[70], who used the Wilkinson’s catalyst, and either a chiral co-
substrate or a chiral ligand. However, these catalytic systems afforded modest results in 
terms of conversion and enantioselectivity. A remarkable advancement in asymmetric 
transfer hydrogenation appeared with the introduction of Noyori’s ruthenium based 
catalyst.[71] The η6-arene piano stool complex of Noyori was successfully applied in the 
asymmetric transfer hydrogenation of ketones,[67,71] and inspired related complexes 
bearing amino alcohols,[72] or C2-symmetric diphosphines/diamines as ligands,[73] formic 
12 
 
acid/triethylamine mixtures were also successfully employed instead of isopropanol as a 
hydride source.[74] Noyori’s ruthenium (II) based catalysts and analogous catalysts such 
as [η5-Cp*M(TsDPEN)Cl] (M=Ir, Rh)[75–77] are probably the most prominent catalysts for 
the asymmetric transfer hydrogenation of ketone substrates. 
Imine reduction by transfer hydrogenation is generally carried out using either 
isopropanol, formic acid or formate salts as reducing agents and ruthenium, iridium or 
rhodium based catalysts.[65] Grigg et al. reported in 1981 the use of Wilkinson's catalyst 
for the transfer hydrogenation of aldimines to secondary amines, using isopropanol as 
the hydride source.[78] Jones et al. reported in the late 1980s the ruthenium catalyst 
precursor Ru3(CO)12 for the transfer hydrogenation of benzylideneaniline.[79]  
The Shvo’s diruthenium complex[80] was utilized for the ATH of imines  and  
investigated by Casey[81,82] and Bäckvall.[83–85] 
The introduction of the Noyori’s ruthenium (II) based catalyst brought improved 
results in the ATH of imine.[86] Different isoquinolines and other cyclic and non-cyclic 
imines were reduced with up to 97% ee using formic acid-triethylamine as a hydride 
source. The reactivity of the catalyst was much higher for imine reduction compared to 
ketone reduction. 
In the last 2 decades, a range of ligands and many successful catalysts have been 
developed for the ATH of ketones and imines.[68,87] The increasing demand for efficient 
and environmentally-friendly chemistry encouraged also the development of water 
compatible catalysts.[88] Deng et al. reported the first examples for asymmetric transfer 
hydrogenation in water, employing Noyori’s ruthenium (II) TosDPEN piano stool 
complex for the reduction of a  range of cyclic and a few acyclic imines with good to 
excellent ee using HCO2Na as a hydride source and sulfonated analogue of the ligand 
for improved water solubility.[89] Modified versions of the complex for improved water 
solubility were also investigated in further studies.[90,91] Investigation on the influence 
of the pH  for the ATH in water, were conducted from Xiao in catalytic systems for 
ketone and[92] and quinoline reduction.[93] The reduction of dihydroisoquinoline-based 
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scaffolds can be considered as a model reaction for the evaluation of new catalysts. 
(Scheme 1.1). 
 
Scheme 1.1 ― Asymmetric transfer hydrogenation of cyclic imine.  
By anchoring a related complex with an achiral ligand moiety bound to a M-arene 
fragment  inside a protein scaffold and subsequent chemo-genetic optimization, 
artificial transfer hydrogenases (ATHases) were developed by the Ward group for the 
reduction of cyclic imines.[45] A range of three-legged piano stool complexes of Rh, Ir[77] 
and Ru[67] are highly active in the asymmetric transfer hydrogenation of imines. 
Considering the robustness of the Cp* moiety[94,95] and aiming at the fast generation of 
large artificial cofactor libraries, a new strategy to link the catalyst through the Cp* 
moiety to biotin, was employed.[96] This concept is discussed in more detail in chapter 5 
of this thesis. 
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1.4 Scope of the thesis 
The goals of this thesis are to improve and explore the potential of artificial transfer 
hydrogenases (ATHases) for new applications. The use of [(ηn-arene)M(ligand)] (M= 
Rh, Ru, Ir) complexes as catalysts for the creation of ATHases has been successfully 
demonstrated for several applications in the Ward group. In the light of these reliable 
ATHases, the objective of this thesis are: 
 
1. Employ the ATHases for NADH regeneration in coupled enzymatic 
transformations to overcome the mutual inhibition between an organometallic 
catalyst and an enzyme. 
 
2. Investigate the stereoselectivity of the ATHase in NAD+ reduction 
 
 
3. Explore new strategies towards increasing the chemical diversity of ATHases  
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2.1 Abstract  
Nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide 
phosphate [NAD(P)H] constitute a major cost factor in preparative biotransformations. 
The development of efficient methods for their regeneration with cheap reducing 
equivalents has been an area of intense research in the last decades. Methods explored 
include chemical, electrochemical, and photochemical approaches. None of the 
methods to regenerate NADH has reached efficiency comparable with enzymatic 
regeneration (e.g. formate dehydrogenase), which remains the method of choice for 
most applications.  
In this review, we summarize primarily organometallic-based approaches for NADH 
regeneration methods which include non-enzymatic steps, before moving on to the 
most recent developments in synthetic NADH related transformations. We highlight 
the frequent problem of mutual inactivation between the organometallic catalyst for 
NADH regeneration and the corresponding NADH dependent downstream enzyme. 
Potential remedies are discussed, such as the compartmentalization of the 
organometallic complex.  
 
2.2 Introduction 
Ever since the groundbreaking work by Abril and Whitesides[1] and Steckhan and 
colleagues[2] on metal mediated nicotinamide adenine dinucleotide (NAD+) 
regeneration the field has blossomed and has been reviewed extensively.[3–12] While 
numerous metal-catalysts have been reported for the efficient reduction of the 
pyridinium moiety, several studies to date were performed on NAD+ (or analogs 
thereof) in the absence of the nicotinamide adenine dinucleotide (NADH) dependent 
enzyme. Indeed, combining both enzyme and organometallic catalyst often lead to 
deactivation of one or both catalytic systems. In this context and following a selection 
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of historically relevant abiotic NADH regeneration systems, we present the most 
promising means to overcome the mutual inhibition challenge.  
 
2.3 Pioneering non-enzymatic approaches for the regeneration of 
nicotinamide adenine dinucleotide phosphate [NAD(P)H] 
The first electro-enzymatic regeneration of NAD(P)H was reported by the group of 
Whitesides. For this purpose, they relied on a tungsten cathode to reduce either a 
disulfide to the corresponding dithiol[13] or methyl viologen[14] to provide the reducing 
equivalents for the enzymatic reduction of NAD+ or nicotinamide adenine dinucleotide 
phosphate (NADP+) with either lipoamide dehydrogenase or ferredoxin NADP 
reductase, respectively. This indirect approach allowed to overcome problems 
encountered in the direct electrochemical reduction, such as insufficient 
regioselectivity and radical dimerization.[15] The NADH produced served for the 
concurrent reduction of pyruvate with lactate dehydrogenase. The methyl viologen 
mediated NADPH regeneration was coupled to the glutamic dehydrogenase catalyzed 
formation of glutamate from α-ketoglutarate. 
The first example of indirect chemical regeneration of NADH, was also reported by 
Whitesides' group in 1981. They employed a water soluble organometallic diphosphine 
rhodium(I) catalyst, to convert pyruvate to lactic acid using H2 (2.72 atm) as reducing 
agent. In the presence of lactate dehydrogenase, NAD+ was reduced to NADH, thus 
enabling the stereoselective reduction of (1R,4S)-Norcamphor with horse liver alcohol 
dehydrogenase (Figure 2.1).[1] They note that the efficiency of the system is limited by 
the modest activity (TOF) of the rhodium complex in the pyruvate reduction (TOF ≈ 10 
h-1, TON = 1500), which nevertheless enables high productivity (TON). The 
deactivation of the rhodium complex by free thiol groups present on the enzymes was 
hypothesized. The addition of a fresh batch of the complex was required to complete 
the reaction.  
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Figure 2.1 ― The first example of NADH regeneration involving a metal-catalyzed step.[1] 
One of the first attempts to regenerate NADH by a photochemical reduction was 
reported by Kiwi in 1981. Here, [Ru(bpy)3]2+ was activated by irradiation with visible 
light, in the presence of TEA which served as the electron donor (Figure 2.2).[16] In 
contrast to their proposed final disproportionation step of the NAD radicals to NAD+ 
and NADH,[17] Steckhan subsequently showed that the radical dimerises practically 
exclusively to yield the non-active (NAD)2.[18] 
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Figure 2.2 ― Proposed photochemical NADH regeneration with [Ru(bpy)3]2+ as catalyst.[16] 
Steckhan was the first to report an indirect electrochemical NADH regeneration 
method. In this system, a [Rh(bpy)3]3+ catalyst is reduced electrochemically to 
[Rh(bpy)2]+ which subsequently reduces NAD+ in  buffered aqueous medium which 
serves as a proton source (Figure 2.3). The system was coupled to horse liver alcohol 
dehydrogenase (HLAD) catalyzed ketone reduction.[19] The use of a [Rh(bpy)3]3+ 
mediator prevents the formation of NAD radicals. Indeed, the direct electrochemical 
reduction of NAD+, requires a potential of > -1.1 V vs. the Ag/AgCl electrode, 
potentially leading to side-products, including the NAD dimer. In the presence of the 
redox-mediator, the potential can be reduced to -850 mV vs. Ag/AgCl electrode. The 
authors identified a passivation of the cathode due to the deposition of 
[Rh(bpy)2(H2O)2]Cl or [Rh(bpy)2(OH)2]Cl leading to low TONs with respect to Rh 
(TON = 2.2). Lacking enzyme activity as a possible cause for the low productivity was 
excluded. 
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Figure 2.3 ― First example of an indirect electrochemical NADH regeneration using an organometallic 
mediator.[19]  
Subsequently, Steckhan reported a photochemical system similar to Kiwi's whereby 
[Ru(bpy)3]2+ (used as sensitizer) is activated by visible light.[18] In the presence of TEOA, 
[Rh(bpy)3]3+ is converted to [Rh(bpy)2]+ and reduces NAD+. In subsequent work, they 
reported an improved version of the electrochemical regeneration. The improvement 
was mainly achieved by tuning the ligand: substituting the bipyridine by bipyridyl-5-
sulfonic acid, allowed to reduce the reduction potential to -730 mV vs. Ag/AgCl 
thereby overcoming the formation of NAD radicals. A TOF of 0.5 h-1 and a TON of 19 
with respect to Rh were achieved in the coupled reduction of cyclohexanone to 
cyclohexanol by HLAD.[20] 
Importantly, Steckhan introduced [Cp*Rh(bpy)Cl]+ to the arena of NADH regeneration. 
Compared to previous systems, the coupling of this catalyst with LDH shows 20 times 
higher reduction rates (TOF = 5 h-1, TON = 14 in respect to Rh) in the conversion of 
pyruvate.[2]  
In the latter system, the hydride [Cp*Rh(bpy)H]+ is the species responsible for NAD+ 
and NAD(P)+ reduction. Instead of using electrochemical means of production from 
[Cp*Rh(bpy)Cl]+, it can be generated by ligand substitution using sodium formate as 
hydride source in a purely chemical regeneration system (Figure 2.4).[21] For NADH and 
NADPH regeneration at 38°C the reported TOF is 82. It should be noted that sodium 
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formate had been introduced previously by Whitesides as a preparative stoichiometric 
reagent for the enzymatic regeneration of NAD+ with formate dehydrogenase.[22] 
 
Figure 2.4 ― Regeneration of NAD(P)H with [Cp*Rh(bpy)]2+ using formate as chemical hydride 
source.[21] 
 
2.4 Recent developments for NAD(P)H and NAD(P)+ 
regeneration 
The initial examples of NAD(P)H regeneration involving non-enzymatic steps, rely 
largely on rhodium―and ruthenium-based catalysts. Numerous other studies have 
been published in the past 20 years. Metals investigated for the reduction and oxidation 
of  NAD+/NADH  or analogues  (in solution or as electrode materials) include Co,[23–25] 
Mn,[26] Fe,[27] Pd-Au,[28] Pt-C,[29] Ni-C,[29] Cu, Au, Pt-Au,[30] Re,[31,32] Cu-Hg.[33] 
Recent reports feature increasingly iridium as the active metal center and address 
additionally the reverse reaction – the catalytic non-enzymatic oxidation of NAD(P)H 
under the simultaneous formation of metal hydrides.  
Fukuzumi  and co-workers[34] reported an efficient system where a [C-N] 
cyclometalated complex [Cp*Ir(4-(1H-pyrazol-1-yl)benzoic acid)H2O]SO4 can 
regenerate NADH under mild conditions (pH 6-8) utilizing H2 as the hydride source at 
room temperature and ambient pressure (Figure 2.5).  A TON of 9.3 at pD 8.0 was 
reported for an NMR experiment at high conversion after 90 min. Under moderately 
acidic conditions, the same complex catalyzes the oxidation of NADH (i.e. the 
microscopic reverse reaction). The TON was determined with 6.3 after 20 min. at a pD 
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of 4.6 and at high conversion. This offers interesting opportunities for catalysis in a 
biological environment since the hydride is transferred to the metal complex, before 
combining with a proton from the solvent to release H2. It is believed that the change 
in pH leads to protonation of the carboxylate group on the ligand, which modifies the 
electronic properties of the ligand and alters the total charge of the complex. 
Regeneration of NADH with this complex can also be accomplished with alcohols as 
reductants under basic aqueous conditions (pH 8.5-10) yielding the corresponding 
carbonyl compounds as 'byproducts'.[35] 
 
Figure 2.5 ― NAD+ reduction (neutral conditions) and NADH oxidation (acidic conditions) with a 
cyclometallated pianostool complex.[34] 
Shortly thereafter, Sadler showed that an organometallic ruthenium- or iridium 
catalyst can be employed for the reduction of pyruvate with NADH as the hydride 
source, thus mimicking the activity of lactate dehydrogenase.[36] In particular, the 
organometallic complexes [(η6-hmb)Ru(bmp)Cl]PF6 (hmb=hexamethylbenzene, 
bpm=2,2’-bipyrimidine) and [CpxphIr(phen)Cl]PF6 (xph= η5-C5Me4C6H5, phen=1,10-
phenanthroline) are two functional mimics of lactate dehydrogenase (for the iridium 
complex, a TON of 75 was reached) (Figure 2.6). The complex [Cp*Ir(phen)Cl]PF6 was 
employed to catalyze the reduction of quinones in a biomimetic reaction of ubiquinone 
oxidoreductase.[37] Sadler analyzed the influence of the nature of the arene cap and the 
N,N-bidentate ligand for Noyori type ruthenium complexes. The activity of the 
complex for NADH oxidation was particularly high when benzene was used as an 
arene cap and the chelating aminosulfonamide ligand carried electron poor 
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sulfonamides.[38] The oxidation of NADH to NAD+ was further performed in aqueous 
solution with the osmium containing pianostool complex [(η6-p-cym)Os(Impy-
NMe2)Cl]PF6 (p-cym= para-cymene, Impy=iminopyridine).[39] In preceding work, 
Sadler and co-workers[40] reported the application of  different ruthenium complexes 
for the generation of NADH under physiological conditions using formate as reducing 
agent. 
 
Figure 2.6 ― NADH oxidation coupled with pyruvate reduction. The resulting systems present lactate 
dehydrogenase activity.[36] 
An iron(III) porphyrin complex was introduced by Gröger for the oxidation of 
NAD(P)H.[41] This water soluble organometallic catalyst is able to oxidize both NADH 
and NAD(P)H with molecular O2 from air as the electron acceptor reaching a TON of 
48-50 (Figure 2.7). Efficient alcohol oxidation was achieved in conjunction with an 
alcohol dehydrogenase. Tests for H2O2 were negative, which accordingly did not need 
to be decomposed by the addition of a catalase. No mutual deactivation of 
metalloporphyrin and enzyme was reported. 
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Figure 2.7 ―  a) NAD(P)H oxidation by a biomimetic organometallic complex; b) water soluble iron(III) 
porphyrin for NAD(P)H oxidation.[41]  
Hollmann has been very active in the field of cofactor regeneration. He recently 
reported on coupling the well-established [Cp*Rh(Bpy)(H2O)]2+ catalyst for NADH 
regeneration with cyclohexanone reduction catalysed by alcohol dehydrogenase from 
thermophile Thermus sp. ATN1 (TADH) (Figure 2.8). Instead of formate, he relied on 
phosphite as the stoichiometric reducing agent reaching a TOF of 21 h-1.[42] Phosphite 
had previously been reported for enzymatic NADH regeneration with phosphite 
dehydrogenase.[43] While the authors observe product inhibition for the enzyme, no 
inactivation of the rhodium complex or of the enzyme was mentioned.  
Hollmann and co-workers[44] also reported the use of a Noyori-type rhodium catalyst 
[Cp*Rh(TsDPEN)Cl], immobilized on polyethylene solid support, for the regeneration 
of NADH with  a TOF of 2.5 h-1.  
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Figure 2.8 ― Chemical NADH regeneration using phosphite as hydride source, coupled with enzymatic 
alcohol dehydrogenase.[42] 
A photochemical approach employing flavin as photosensitizer for the regeneration of 
NADH was reported by Park. Electrons are provided by TEOA and 
[Cp*Rh(bpy)(H2O)]2+ serves once again as organometallic mediator. The NADH 
regeneration system was coupled to an enzymatic reaction for the formation of L-
glutamate from α-ketoglutarate with GDH (L-glutamate dehydrogenase) (Figure 2.9).[45] 
No inactivation of enzyme or mediator was reported.  
In a successive investigations, they used different photosensitizers such as Eosin-Y or 
dot-coated silica beads, the former also in conjunction with NAD+ analogues.[46,47] A 
related photochemical regeneration of NADPH was recently coupled with cytochrome 
P450 catalyzed the O-dealkylation. In this case, the author mention the inactivation of 
the cytochrome P-450 by [Cp*Rh(bpy)(H2O)]2+.[48]  
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Figure 2.9 ― NADH regeneration induced by visible light, mediate from organometallic rhodium 
catalyst, coupled with an enzymatic  ʟ-glutamate dehydrogenase.[45] 
 
2.5 Mutual inactivation of the organometallic catalyst and the 
enzyme 
A challenge, often encountered in combining transition metal-based NAD(P)H 
regeneration with enzymatic NAD(P)H-dependent processes is the mutual deactivation 
of the organometallic catalyst and the enzyme. 
Some of the publications summarized above, mention low TONs and suggest that this 
may be due to the limited compatibility of organometallic and enzymatic catalysts. We 
present below a selection of studies aimed at addressing this problem specifically. 
To the best of our knowledge, Schmid and Fish were the first to highlight the mutual 
inactivation between [Cp*Rh(bpy)(H2O)]2+ and an NADH dependent enzyme.[49] The 
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model system they investigated was the [Cp*Rh(bpy)(H2O)]2+ mediated regeneration of 
an NADH mimic with the enzymatic hydroxylation of 2-hydroxybiphenyl to the 
corresponding catechol catalysed by 2-hydroxybiphenyl-3-monooxygenase (HbpA) 
(Figure 2.10). 
Upon combining the organometallic cofactor regeneration system with the 
monooxygenase, no product formation was detected. The authors suggest that the 
interaction between the accessible nucleophilic amino acid residues (i.e. lysine (-NH2) 
and cysteine (-SH)) of the enzyme (HbpA) and the soft metal center of the 
organometallic catalyst causes deactivation of the rhodium catalyst. 
To overcome the problem, they immobilized the enzyme on a polymer support flanked 
with epoxide moieties which react with exposed nucleophilic amino acid residues. The 
resulting coupled system enabled substantial hydroxylation when natural NAD+ was 
employed.  
 
Figure 2.10 ― Organometallic regeneration of a mimic NADH coupled with enzymatic 
monooxygenase.[49] 
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Lütz and coworkers investigated in detail the problem of mutual inactivation between 
the organometallic mediator [Cp*Rh(bpy)(H2O)]2+ and an alcohol dehydrogenase from 
Lactobacillus brevis (Lb-ADH) and proposed a compartmentalization of the two 
entities.[50] 
For this purpose, they scrutinized the interaction of the piano stool complex with 
isolated amino acids to evaluate their influence. Interestingly, he identified tryptophan, 
in addition to the traditional suspects histidine and cysteine that lead to strong 
deactivation of the pianostool moiety. Compartmentalization was achieved by 
immobilizing the organometallic mediator used for the electrochemical regeneration as 
part of a water-soluble polymer and the enzyme on Sephabeads®. Additionally, a 
cellulose membrane, permeable only to NADH and substrate, was introduced to 
physically separate both catalysts (Figure 2.11). Based on recovered mediator after the 
reaction they calculated a feasible turnover number of >200. 
 
35 
 
 
 
  
 
36 
 
  
  
Figure 2.11 ― Electroenzymatic reactor with separation of electrochemical NADH-regeneration and 
enzymatic reaction for the production of p-chloro-(R)-phenylethanol with Lb-ADH.[50] 
Building on previous observations, Hollmann and coworkers investigated the 
inactivation of various enzymes upon addition of [Cp*Rh(bpy)(H2O)]2+. In addition to 
the spatial separation described above, they scrutinized the use of coordinating buffers 
as a potential remedy to mutual inactivation. They found that addition of (NH4)2SO4 
leads to an increased compatibility between the enzyme and the pianostool catalyst 
[Cp*Rh(bpy)(H2O)]2+. Unfortunately, the catalytic NADH regeneration using formate 
was eroded. In stark contrast, the electrochemical regeneration in the presence of 
(NH4)2SO4 remained satisfying.[51] 
More recently, Bergman, Raymond and Toste presented an original supramolecular 
compartmentalization strategy to prevent mutual inactivation. For this purpose, they 
encapsulated the pianostool moiety [CpRu(NCMe)2PMe3]+ (Cp = cyclopentadiene) 
within a supramolecular tetrahedral host cage. As a proof of principle, they developed a 
tandem catalytic process where the organometallic guest [CpRu(NCMe)2PMe3]+ 
catalyses the isomerization of allylic alcohol  to the corresponding aldehyde which is 
subsequently reduced by an alcohol dehydrogenase to the saturated alcohol. A formate 
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dehydrogenase provides the NADH equivalents for the process (Figure 2.12).[52] 
Although this system does not constitute an artificial NADH regeneration systems, it 
highlights the improved compatibility of an organometallic catalyst with enzymes 
upon incorporation into a supramolecular host, to avoid the interaction with free 
amino acid residues from enzyme. 
 
 
Figure 2.12 ― Encapsulation of a ruthenium piano-stool catalyst in a supramolecular cage allows to 
combine a metal-catalyzed allylic isomerization with an enzyme cascade consisting of an NADPH-
dependent alcohol dehydrogenase (ADH) and formate dehydrogenase (FDH).[52] 
An alternative approach to address the problem of mutual inactivation was reported by 
Hollmann, Turner and Ward. They incorporated an Ir-piano stool complex for NAD+ 
regeneration into streptavidin, thereby creating an artificial metalloenzyme and 
efficiently compartmentalizing the NADH dependent downstream enzyme and the Ir-
complex.[53] The incorporation was realized by exploiting the biotin streptavidin 
technology.[54] 
In the same study it was observed that the catalyst [Cp*Ir(biot-p-L)Cl] is significantly 
more active in NADH regeneration than the well-established [Cp*Rh(bpy)(H2O)]2+. By 
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incorporation of the iridium catalyst into a streptavidin mutant S112A, the system was 
coupled to the hydroxybiphenyl monooxygenase (HbpA) catalyzed hydroxylation; 
efficient hydroxylation was achieved under relevant biological conditions (pH 7.5, 
30°C, open air) (Figure 2.13) with a TON of >100 in respect to[Cp*Ir(biot-p-L)Cl]. 
 
 
  
Figure 2.13 ― An artificial metalloenzyme for the NADH regeneration fully compatible with 
hydroxybiphenyl monooxygenase (HbpA).[53] 
 
2.6 Outlook 
Having identified the underlying principles of mutual inhibition, several 
complementary compartmentalization strategies have been developed in recent years: 
polymer immobilization, selective membranes, supramolecular encapsulation and 
anchoring within a macromolecular scaffold. Thus far however, the most promising 
organometallic regeneration systems rely on precious metals: rhodium and iridium 
occupying a place of choice. The next step will be to implement the above strategies to 
base-metals. 
39 
 
 
2.7 References 
(1)  Abril, O.; Whitesides, G. M. J. Am. Chem. Soc. 1982, 104, 1552–1554. 
(2)  Ruppert, R.; Herrmann, S.; Steckhan, E. Tetrahedron lett. 1987, 28, 6583–6586. 
(3)  Hollmann, F.; Arends, I. W. C. E.; Buehler, K. ChemCatChem 2010, 2, 762–782. 
(4)  Mcskimming, A.; Colbran, S. B. Chem. Soc. Rev. 2013, 42, 5439–5488. 
(5)  Kochius, S.; Magnusson, A. O.; Hollmann, F.; Schrader, J.; Holtmann, D. Appl. 
Microbiol. Biotechnol. 2012, 93, 2251–2264. 
(6)  Hollmann, F.; Hofstetter, K.; Schmid, A.; Care, D.; Specialties, S.; Ag, G. TRENDS 
in Biotech. 2006, 24, 163–171. 
(7)  Kohlmann, C.; Wolfgang, M.; Lütz, S. J. Mol. Catal. B Enzym. 2008, 51, 57–72. 
(8)  Rodriguez, C.; Lavandera, I.; Gotor, V. Curr. Org.Chem. 2012, 16, 2525–2541. 
(9)  Truppo, M. D. Compr. Chirality 2012, 7, 46–70. 
(10)  Holtmann, D.; Schrader, J. In Modern biooxidation. Enzymes, Reactions and 
Applications; Schmid, R. D.; B.Urlacher, V., Eds.; WILEY-VCH: Weinheim, 
2007; pp. 265–290. 
(11)  Lütz, S. In The Handbook of Homogeneous Hydrogenation; de Vries, J. G.; 
Elsevier, C. J., Eds.; WILEY-VCH: Weinheim, 2007; pp. 1471–1482. 
(12)  Weckbecker, A.; Gröger, H.; Hummel, W. In Advances in Biochemical 
Engineering/Biotechnology; Scheper, T., Belkin, S., Doran, P.M., Endo, I., Gu, 
M.B., Hu, W.S., Mattiasson, B., Nielsen, J., Stephanopoulos, G.N., Ulber, R., 
Zeng, A.-P., Zhong, J.-J., Zhou, W., Ed.; Springer: Heidelberg, 2009; pp. 195–242. 
40 
 
(13)  Shaked, Z.; Barber, J. J.; Whitesides, G. M. J. Org. Chem. 1981, 46, 4100–4101. 
(14)  DiCosimo, R.; Wong, C.-H.; Lacy Daniels; M., G.; Whitesides J. Org. Chem. 
1981, 46, 4622–4623. 
(15)  Schmakel, C. O.; Santhanam, K. S. V; Elving, P. J. J. Am. Chem. Soc. 1975, 97, 
5083–5092. 
(16)  Kiwi, J. J. Photochem. 1981, 16, 193–202. 
(17)  Land, E. J.; Swallow, A. J. Biochem. 1969, 8, 2117–2125. 
(18)  Wienkamp, R.; Steckhan, E. Angew. Chem. Int. Ed. 1983, 22, 497. 
(19)  Wienkamp, R.; Steckhan, E. Angew. Chem. Int. Ed. 1982, 21, 782–783. 
(20)  Franke, M.; Steckhan, E. Angew. Chem. Int. Ed. 1988, 27, 265–267. 
(21)  Ruppert, R.; Herrmann, S.; Steckhan, E. J. Chem. Soc., Chem. Commun. 1988, 1, 
1150–1151. 
(22)  Shaked, Z.; Whiteside, G. M. J. Am. Chem. Soc. 1980, 102, 7104. 
(23)  Fukuzumi, S.; Kitano, T. J. Chem. Soc. Perkin Trans. 1991, 41–45. 
(24)  Hilt, G.; Steckhan, E. J. Chem. Soc., Chem Commun. 1993, 1706–1707. 
(25)  Kim, J. A.; Kim, S.; Lee, J.; Baeg, J.; Kim, J. Inorg. Chem. 2012, 51, 8057–8063. 
(26)  Fukuzumi, S.; Kotani, H.; Prokop, K. A.; Goldberg, D. P. J. Am. Chem. Soc. 2011, 
133, 1859–1869. 
(27)  Fukuzumi, S.; Kotani, H.; Lee, Y.-M.; Nam, W. J. Am. Chem. Soc. 2008, 130, 
15134–15142. 
41 
 
(28)  Gopalan, A.; Ragupathy, D.; Kim, H.; Manesh, K. M.; Lee, K. Spectrochim. Acta 
Part A 2009, 74, 678–684. 
(29)  Ali, I.; Gill, A.; Omanovic, S. Chem. Eng. J. 2012, 188, 173–180. 
(30)  Damian, A.; Maloo, K.; Omanovic, S. Chem. Biochem. Eng. Q. 2007, 21, 21–32. 
(31)  Kobayashi, A.; Takatori, R.; Kikuchi, I.; Konno, H.; Sakamoto, K.; Ishitani, O. 
Organometallics 2001, 20, 3361–3363. 
(32)  Kobayashi, A.; Konno, H.; Sakamoto, K.; Sekine, A.; Iida, M.; Ishitani, O. Chem. 
Eur. J. 2005, 11, 4219–4226. 
(33)  Munteanu, G.; Dempsey, E.; Mccormac, T.; Munteanu, C. J. Electroanal. Chem. 
2012, 665, 12–19. 
(34)  Maenaka, Y.; Suenobu, T.; Fukuzumi, S. J. Am. Chem. Soc. 2012, 134, 367–374. 
(35)  Maenaka, Y.; Suenobu, T.; Fukuzumi, S. J. Am. Chem. Soc. 2012, 134, 9417–
9427. 
(36)  Betanzos-lara, S.; Liu, Z.; Habtemariam, A.; Pizarro, A. M.; Qamar, B.; Sadler, P. 
J. Angew. Chem. Int. Ed. 2012, 51, 3897–3900. 
(37)  Liu, Z.; Deeth, R. J.; Butler, J. S.; Habtemariam, A.; Newton, M. E.; Sadler, P. J. 
Angew. Chem. Int. Ed. 2013, 52, 4194–4197. 
(38)  Soldevila-barreda, J. J.; Bruijnincx, P. C. A.; Habtemariam, A.; Clarkson, G. J.; 
Deeth, R. J.; Sadler, P. J. Organometallics 2012, 31, 5958–5967. 
(39)  Fu, Y.; Romero, J. M.; Habtemariam, A.; Snowden, M. E.; Song, L.; Clarkson, G. 
J.; Qamar, B.; Pizarro, A. M.; Unwin, P. R.; Sadler, P. J. Chem. Sci. 2012, 3, 2485–
2494. 
42 
 
(40)  Yan, Y. K.; Melchart, M.; Abtemariam, A.; Peacock, A. F. A.; Sadler, P. J. J. Biol. 
Inorg. Chem. 2006, 11, 483–488. 
(41)  Maid, H.; Böhm, P.; Huber, S. M.; Bauer, W.; Hummel, W.; Jux, N.; Gröger, H. 
Angew. Chem. Int. Ed. 2011, 50, 2397–2400. 
(42)  Grau, M. M.; Poizat, M.; Arends, I. W. C. E.; Hollmann, F. Appl. Organomet. 
Chem. 2010, 24, 380–385. 
(43)  Vrtis, J. M.; White, A. K.; Metcalf, W. W.; Donk, W. A. Van Der; V, S. M. A.; 
On, H. J. Am. Chem. Soc. 2001, 123, 2672–2673. 
(44)  Torres, M. De; Dimroth, J.; Arends, I. W. C. E.; Keilitz, J.; Hollmann, F. 
Molecules 2012, 17, 9835–9841. 
(45)  Nam, D. H.; Park, C. B. Chembiochem 2012, 13, 1278–1282. 
(46)  Lee, S. ha; Ryu, J.; Nam, D. H.; Park, C. B. Chem. Comm. 2011, 47, 4643–4645. 
(47)  Lee, S. H.; Lee, H. J.; Won, K.; Park, C. B. Chem. Eur. J. 2012, 18, 5490–5495. 
(48)  Lee, S. H.; Kwon, Y.-C.; Kim, D.-M.; Park, C. B. Biotechnol. & Bioeng. 2013, 110, 
383–90. 
(49)  Lutz, J.; Hollmann, F.; Vinh, T.; Schnyder, A.; Fish, R. H.; Schmid, A. J. 
Organomet. Chem. 2004, 689, 4783–4790. 
(50)  Hildebrand, F.; Lütz, S. Chem. Eur. J. 2009, 15, 4998–5001. 
(51)  Poizat, M.; Arends, I. W. C. E.; Hollmann, F. J. Mol. Catal. B Enzym. 2010, 63, 
149–156. 
(52)  Wang, Z. J.; Clary, K. N.; Bergman, R. G.; Raymond, K. N.; Toste, F. D. Nat. 
Chem. 2013, 5, 100–103. 
43 
 
(53)  Köhler, V.; Wilson, Y. M.; Dürrenberger, M.; Ghislieri, D.; Churakova, E.; 
Quinto, T.; Knörr, L.; Häussinger, D.; Hollmann, F.; Turner, N. J.; Ward, T. R. 
Nat. Chem. 2013, 5, 93–9. 
(54)  Ward, T. R. Acc. Chem. Res. 2011, 44, 47–57.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
 
 
45 
 
Chapter 3 
________________________ 
Synthetic cascades are enabled by combining 
biocatalysts with artificial metalloenzymes 
3.1 Preamble 
With the aim of performing in vivo catalysis, i.e. employing catalytic organometallic 
chemistry in biological systems, the activity of the corresponding catalyst in the 
cellular environment needs to be assured. Therefore, one needs to consider that the 
catalyst will interact with the cellular matrix. In order to perform directed evolution of 
artificial transfer hydrogenases, one of the challenges that needs to be overcome 
consists of the often detrimental interaction between cellular proteins and the 
synthetic metal complex. Mutual inactivation between organometallic catalyst and 
enzymes is an event that occurs frequently when these two catalytic systems are 
brought together. This is mainly due to the interactions of nucleophilic amino acid side 
chain functions on the protein surface (steming e.g. from histidine, cysteine) and the 
metal catalyst.[1,2] To overcome this problem, the active organometallic catalyst 
[Cp*Ir(biot-p-l)Cl] was incorporated  into streptavidin mutants to shield it from the 
enzymatic tandem catalysis partner and thereby prevent inhibitory interactions. To 
validate this concept, the resulting artificial transfer hydrogenases (ATHase) were 
tested for the regeneration of NADH coupled with the concurrent action of 2-
hydroxybiphenyl monooxygenase (HbpA), which performs the ortho-specific 
hydroxylation of an α-substituted phenol to the corresponding catechol and requires 
NADH as a redox equivalent (Scheme 3.1).  
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Figure 3.1 ― Hydroxylation of 2-hydroxybiphenyl, coupled to ATHase-catalysed NADH regeneration. 
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3.2 Abstract  
Enzymatic catalysis and homogeneous catalysis offer complementary means to address 
synthetic challenges, both in chemistry and in biology. Despite its attractiveness, the 
implementation of concurrent cascade reactions which combine an organometallic 
catalyst with an enzyme has proven challenging, due to the mutual inactivation of both 
catalysts. To address this, we show that incorporation of a d6-piano stool complex 
within a host protein affords an artificial transfer hydrogenase (ATHase) which is fully 
compatible with and complementary to natural enzymes, thus enabling efficient 
concurrent tandem catalysis. To illustrate the generality of the approach, the ATHase 
was combined with various NADH-, FAD- and heme-dependent enzymes resulting in 
orthogonal redox cascades. Up to three enzymes were integrated in the cascade and 
combined with the ATHase with a view to achieving i) a double stereoselective amine 
deracemisation, ii) a horseradish peroxidase-coupled readout of the transfer 
hydrogenase activity towards its genetic optimization iii) the formation of ʟ-pipecolic 
acid from ʟ-lysine and iv) regeneration of NADH to promote a monooxygenase-
catalyzed oxyfunctionalization reaction. 
3.3 Introduction 
Cellular biochemistry requires the orchestration of metabolic pathways in which many 
enzyme-catalysed processes are able to function simultaneously, resulting in the 
production of a wide range of primary and secondary metabolites within the cell. In an 
attempt to construct artificial cells, usingthe principles of synthetic biology, 
compartmentalization of cellular processes will need to be mimicked in order to allow 
cascade reactions to take place in parallel in an efficient manner.[3–8] Whereas enzymes 
have evolved in concert and in complex media, problems and mutual inactivation are 
often encountered upon combining chemocatalyst with biocatalysts.[9–11] Such 
incompatibility may be circumvented by performing cascades in sequential steps or by 
site-isolation of the individual catalysts through immobilization, heterogeneous or 
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biphasic reaction conditions, encapsulation and so on.[12–26] Recently, we have described 
one approach to cellular compartmentalization in which an E. coli cell was engineered 
to simultaneously express an intracellular enzyme (monoamine oxidase) and also bind 
palladium nanoparticles in its outer membrane, thereby allowing efficient chemo-
enzymatic deracemisation of amines[26] Artificial metalloenzymes which result from 
encapsulation of an organometallic catalyst within a protein scaffold, have been shown 
to combine attractive features of both chemocatalysts and biocatalysts for single-step 
transformations[27–34] In the context of concurrent cascade reactions, we reasoned that 
the artificial cofactor may be effectively shielded by its host protein, thus preventing 
the mutual inactivation commonly encountered upon combining an organometallic 
catalyst with an enzyme (Figure 3.1). To test the validity of the concept, we examined 
the combination of an artificial transfer-hydrogenase (ATHase) and a monooxygenase 
(Figure 3.2). For this purpose, we rely on the incorporation of a biotinylated 
[Cp*Ir(Biot-p-L)Cl] complex within streptavidin (Sav hereafter) as ATHase using 
sodium formate as hydride source (Figures 3.1 and 3.2).  
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Figure 3.1 ― Reaction cascades resulting from combining an ATHase with a biocatalyst. The 
organometallic transfer-hydrogenation catalyst [Cp*Ir(biot-p-L)Cl] and biocatalyst suffer from mutual 
inactivation thus precluding the implementation of reaction cascades. Relying on the strength of the 
biotin-streptavidin interaction, incorporation of the biotin-bearing complex [Cp*Ir(biot-p-L)Cl] within 
streptavidin (Sav) affords  an ATHase which is fully compatible with and complementary to a variety of 
natural enzymes thus leading to the development of concurrent orthogonal redox cascades. 
 
3.4 NADH regeneration for monooxygenases 
 The chemical and electrochemical recycling of NAD(P)H and analogues has been 
intensively investigated as an alternative to enzymatic regeneration.[1,2,14,35–40] In this 
context, [Cp*Rh(bipy)Cl]+ has emerged as redox mediator or catalyst of choice. 
However, in the presence of the downstream enzyme, mutual inactivation is 
commonly encountered.[1,2] To test the validity of the molecular compartmentalization 
concept outlined in Figure 3.1, we investigated the regeneration of NADH in the 
presence of an NADH-dependent enzyme using an ATHase. Although significantly 
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more active than [Cp*Rh(bipy)Cl]+ for the NADH regeneration in the absence of an 
NADH-dependent enzyme, [Cp*Ir(Biot-p-L)Cl] was rapidly deactivated in the presence 
of 2-hydroxylbiphenyl monooxygenase (HbpA from Pseudomonas azaleica, an NADH- 
and FAD-dependent enzyme). In the presence of Sav, however, the mutual inactivation 
of [Cp*Ir(Biot-p-L)Cl] and HbpA was efficiently prevented and robust hydroxylation 
activity was achieved (Table 3.1, Figure 3.2). We conclude that Sav shields the ATHase 
from the downstream enzyme, allowing the NADH regeneration with formate as 
hydride source (KM(app) = 165 µM (±6 µM), kcat(app) = 1.37 min-1 (± 0.01 min-1), Supporting 
Information Figure 3.7). Full conversion of 2-hydroxybiphenyl to 2,3-
dihydroxybiphenyl was accomplished in 2 h with a crude enzyme extract (Figure 3.2 
and Table 3.1) and Supporting Information Figure 3.5).  
Table 3.1 Orthogonal redox cascade combining ATHase with monooxygenases. 
Entry Substrate Product Sav-Mutant Monooxygenase Conv. (a) (%) 
1 
  
_ HbpA 3 
2 
  
S112A HbpA >99 
a) Conversion determined by HPLC 
The system could be run either in pure aqueous phase or as a biphasic system with 1-
decanol functioning as a substrate reservoir and product sink, thereby highlighting the 
applicability of the ATHase under a variety of reaction conditions. The biphasic system 
displayed again strong inactivation in the absence of Sav, whereas a TON of > 100 
(versus [Cp*Ir(Biot-p-L)Cl]) was achieved when Sav was present (Supporting 
information Figure 3.6). 
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Figure 3.2 ― Expanding the concept of orthogonal redox cascades to include other enzymes. Concurrent 
regeneration of NADH by the ATHase in the presence of a monooxygenase. 
 
3.5 Outlook 
 We have demonstrated herein that an ATHase consisting of [Cp*Ir(Biot-p-L)Cl] 
anchored within streptavidin mutants is complementary and compatible with a variety 
of redox enzymes relying on NADH, FADH2 and heme cofactors. Such artificial 
metalloenzymes display attractive features which are reminiscent of both biocatalysts 
and chemocatalysts: precious metal reactivity, genetic optimization potential and well-
defined second coordination sphere provided by a protein scaffold. This last feature 
could be further exploited with a view to achieving the immobilization of the entire 
enzyme cascade. 
To optimize such cascades, directed evolution protocols are highly desirable. With this 
goal in mind, we have shown that the ATHase can be integrated with a colorimetric 
coupled assay, leading to the identification of a genetically improved ATHase. These 
proof-of-principle examples open fascinating perspectives towards complementing bio-
catalytic cascades with molecularly compartmentalized organometallic catalysts. 
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3.6 Supporting Information 
General Information 
Chemicals were purchased from Sigma-Aldrich, Acros and TCI and used as received. 
Streptavidin (Sav) mutants were produced, purified and characterised as previously 
described.[41] The Sav used in this work and on which all variants were based was T7-
tagged core Sav described by Gallizia et al.[42]  and here we refer to this as wild-type 
Sav. The corresponding ATHase is also referred to as wild-type (WT). For a detailed 
synthesis procedure of [Cp*Ir(Biot-p-L)Cl] see reference.[43] Commercial enzyme 
preparations were purchased from Sigma. MAO-Nmutants used in this study are 
described elsewhere.[44,45] rac-2-cyclohexylpyrrolidine was prepared from 2-cycloexyl-
1-pyrroline by reduction with NaBH4 in MeOH. 2-cyclohexyl-1pyrroline wa prepared 
according by literature procedure.[46] Pseudooxynicotine was prepared as described in 
reference.[47] 2,3-dihydroxybiphenyl was a kind gift from Prof. Dr. Andreas Schmid (TU 
Dortmund, Dortmund, Germany). L-lysine-13C2 HCl (99% 13C) was obtained from 
Sigma. NMR Experiments were performed at 25°C (MeOH calibration) on Bruker 
Avance III NMR spectrometers operating at 600, 500 or 400 MHz proton frequency. All 
were equipped with direct (600 and 400 MHz) or inverse (500MHz) dual channel 
broadband probe-heads with z-gradients. Chemical shift were referenced to residual 
proton solvent peak (4.773 ppm for H2O, 7,26 for CHCL3).The quantitative constant 
time HSQC experiment was performed using 2048 data points in the F2 and 1024 data 
points in the F+ dimension, corresponding to acquisition time of 155ms in F2 and 34 ms 
in F1. Each increment was recorded with 8 scans resulting in a total experiments time 
of 2h 45min.  HPLC measurements were performend on Agilent (or hp) machines 
equipped with modules from the 1100 and 1200 series and diode array detectors, if not 
indicated otherwise. HPLC columns were used with the appropriate guard columns, if 
not indicated otherwise. Column and conditions are indicated for each compound 
separately. GC measurements were performed on Agilent GCs of the 6890 series 
equipped with FIDs. 
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NAD reduction and HbpA coupled hydroxylation of 2-hydroxybiphenyl 
Stock solutions: Potassium phosphate buffer (KPi) was prepared by dissolving  K2HPO4 
(114.8 mg) and KH2PO4 (590.2 mg) in distilled water (100mL, final conc. 50 mM, pH 
6.0). Then sodium formate was dissolved in phosphate buffer (final 200mM). The pH 
was adjusted with NaOH. Stock solutions of lyophilized streptavidin S112A (Sav 
S112A) corresponding to 1 mM free binding sites (assuming 3 free binding sites per 
tetramer) were prepared by dissolving Sav S112A (21.9 mg) in H2O (1 mL) directly 
before the experiment. The mixture was stirred until all protein was dissolved. The 
stock solutions of the metal complexes were prepared in DMF to the final 
concentration of 1 mM. NAD+ and NADH stock solutions were prepared in H2O to the 
final concentration of 10 mM and stored at -20°C. FAD stock solutions were prepared 
in water to the final concentration of 1 mM. 
HbpA preparation 
The enzyme 2-hydroxybiphenyl-3-monooxygenase (HbpA, E.C.1.14.13.44) was kindly 
supplied by Prof. Dr. Andreas Schmid (TU Dortmund, Dortmund, Germany). The 
enzyme had been produced using Escherichia coli recombinantly expressing HbpA (E. 
coli JM101 pHBP461 containing hbpA) following a published procedure.[48,49] For 
enrichment, the cell crude extracts (cell disruption was achieved by two passages 
through a French Press) were submitted to anion exchange chromatography 
(Streamline DEAE anion exchanger - Pharmacia). HbpA was eluted with 20 mM Tris 
HCl pH 7.5 using a linear gradient of NaCl from 0 to 1 M NaCl. HbpA was recovered in 
pooled fractions at 150 to 200 mM NaCl. The final enzyme preparation (pooled 
fractions) contained partially purified HbpA. Specific activities of purified fractions 
were determined at 30°C, 0.1 mM 2-hydroxybiphenyl and 0.1 mM NADH.[48,49] HbpA 
was stored as a lyophilised powder at -20°C. HbpA-preparation (typically 12.5 mg/mL) 
was dissolved directly before the experiments in KPi buffer (50 mM, pH 7.5).  
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NADH regeneration activity of [Cp*Ir(Biot-p-L)Cl]; [Cp*Ir(Biot-p-L)Cl]Sav with 
[Cp*Rh(Biot-p-L)Cl] 
The activity measurements of the biotinylated metal-complexes (in the absence or 
presence of SAV) for NADH regeneration was carried out in disposable UV cuvettes 
(polystyrene) at 30°C (Shimadzu UV-2401 PC spectrophotometer; Julabo F12 
Refrigerated/Heating Circulator). The reaction buffer (980 µL (or 970 µL for the 
reaction with SAV), 50 mM KPi, 200 mM NaHCO2, pH 7.5) was supplemented with 
[Cp*Ir(Biot-p-L)Cl] or [Cp*Rh(Biot-p-L)Cl], respectively (10 µL of a 1 mM solution in 
DMF). If indicated, SAV-S112A stocksolution (10 µL, 1 mM in free binding sites in 
H2O; 3 free binding sites per tetramer assumed) was added and the mixture was 
incubated at ambient temperature for 15 min. to allow for binding of the metal 
complex to SAV. The reactions were started by addition of NAD (10 µL of a 10 mM 
solution in H2O). The reaction progress was followed spectrophotometrically by 
recording UV spectra or simply by following the absorption change at 340 nm. For 
quantification of NADH formed, the molar absorption coefficient of 6220 M-1 cm-1 was 
used.[50] 
Representative UV spectra of the [Cp*Ir(Biot-p-L)Cl] and of the [Cp*Ir(Biot-p-
L)Cl]Sav mediated reduction of NAD are shown in Figure 3.3. The time courses of 
NAD reduction for all three regeneration catalysts are shown in Figure 3.3 (right) and 
initial rates compared in Table 3.2. 
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Figure 3.3 ― Left: UV-spectra recorded during the [Cp*Ir(Biot-p-L)Cl] (top left) and [Cp*Ir(Biot-p-
L)Cl]SAV (bottom left)-mediated reduction of NAD. Spectra were recorded at 10 sec and 60 sec 
intervals in case of [Cp*Ir(Biot-p-L)Cl] (top left) and [Cp*Ir(Biot-p-L)Cl]SAV (bottom left), respectively. 
Right: Time course of the metal-catalyzed reductions of NAD. [Cp*Ir(Biot-p-L)Cl]: green; [Cp*Ir(Biot-p-
L)Cl]SAV(S112A): red; [Cp*Rh(Biot-p-L)Cl]: black. 
Table 3.2 Comparison of initial rates for graph in Figure 3.3 (right). 
Compound TOF [h-1] relative activity [%] 
[Cp*Rh(Biot-p-L)Cl] 4.3 100 
[Cp*Ir(Biot-p-L)Cl] 276.0 6420 
[Cp*Ir(Biot-p-L)Cl]SAV(S112A) 42.5 988 
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Effect of Sav-S112A on the robustness of the chemoenzymatic 
hydroxylation reactions 
In a first set of experiments the mutual inactivation of [Cp*Ir(Biot-p-L)Cl] and HbpA as 
well as the protecting effect of [Cp*Ir-biot-p-L)Cl]SAV(S112A) was examined. For 
this, spectrophotometric activity assays were performed: To phosphate buffer (1560 µL, 
50 mM, pH 7.5) was added [Cp*Ir(Biot-p-L)Cl] (20 µL of a 1 mM solution in DMF) and 
either SAV-S112A (20 µL, 1 mM free binding sites in H2O; 3 free binding sites per 
tetramer assumed) or H2O (20 µL), respectively. Subsequently the mixtures were 
supplemented with HbpA stock solution (400 µL, 1 mg/mL in 50 mM KPi buffer, pH 
7.5). These mixtures were incubated in a shaking incubator at 30°C. At 1 and 2 hours 
aliquots were taken to measure the residual activity. Residual HbpA activity: An 
aliquot of the incubated mixture (200 µL) was added to a mixture of phosphate buffer 
(740 µL, 50 mM, pH 7.5), NADH stock (30 µL of a 10 mM solution in H2O) and FAD 
(10 µL of a 1 mM solution in H2O) in a disposable UV-cuvette (polystyrene). The 
resulting solution was placed in a UV spectrometer at 30°C and background activity 
was recorded for 1.5 min. Residual substrate-related activity was followed after adding 
2-hydroxybiphenyl (20 µL of a 25 mM methanolic solution) by the decrease in 
absorption at 340nm (NADH). For residual [IrCp*(Biot-p-L)L] activity an aliquot of the 
incubated mixture (100 µL) was added to formate containing buffer (890 µL, 50 mM in 
KPi, 200 mM in NaHCO2, pH 7.5) and the reactions were started by addition of NAD 
(10 µL of a 10 mM solution H2O). Table 3.3 summarizes the residual activities observed 
for the metal- and biocatalyst.  
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Table 3.3 Residual activity of HbpA and Ir-catalyst after co-incubation. 
 residual HbpA activity [%] residual Ir-activity [%] 
 incubation time 
 1h 2h 1h 2h 
[Cp*Ir(biot-p-L)Cl] <1 0 29 0 
[Cp*Ir(biot-p-L)Cl]S112A 62 49 68 57 
Potassium phosphate buffer 98 94 100 100 
 
Both HbpA and [Cp*Ir(Biot-p-L)L] were rapidly deactivated when brought into 
contact. The deactivation was largely alleviated if the Ir-catalyst was preincubated with 
SAV-S112A. Hence, we concluded that indeed, SAV shielded the Ir-complex efficiently 
from interaction with HbpA and thereby protected both catalysts from mutual 
deactivation. 
The effect of SAV-S112A on the chemoenzymatic hydroxylation of 2-
hydroxybiphenyl 
A first set of experiments was performed in aqueous medium: formate containing 
buffer solution (1.68 ml of 50 mM KPi, 200 mM NaHCO2, pH adjusted to 7.5 with 
NaOH) was placed in a 2 mL PP-tube, SAV-S112A stock solution (40 µL, 1 mM free 
binding sites in H2O; 3 free binding sites per tetramer assumed) was added, followed by 
[Cp*Ir(Biot-p-L)Cl] (40 µL, 1 mM in DMF). This mixture was incubated for 15 minutes 
at room temperature. Afterwards, the mixture was supplemented with FAD solution 
(20 µL of a 1 mM solution in H2O) and HbpA stock solution (80 µL, 12.5 mg/ml, 11 
U/ml in KPi buffer). After addition of the substrate 2-hydroxybiphenyl (40 µL of a 25 
mM stock solution in methanol) the reaction was started by addition of NAD (100 µL of 
a 10 mM stock solution in H2O). The reaction mixtures were placed in a thermoshaker 
(TWISTER comfort) and incubated at 30oC and 400 rpm. Samples of 50 µL were 
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withdrawn at the indicated time points, diluted with ACN/water (0.95 mL of a 50:50 
(v/v) mixture containing 0.1% TFA) and analysed by RP-HPLC. (Shimadzu LC-20 
system with a Shimadzu SPD-20A Photo Diode Array detector using a Waters Xterra 
column (RP18, 3.5 μM, 4.6 × 150 mm). The temperature was controlled to 40°C by a 
Shimadzu CTO-20AC column oven. The eluent was acetonitrile/water (50/50) isocratic 
and contained 0.1% TFA; flow rate: 1.1 mL/min, detection wavelength 254 nm). The 
quantification was based on calibration curves using authentic standards. Typical 
chromatograms are shown in Figure 3.4. 
 
Figure 3.4 ― Chromatograms of a typical chemoenzymatic hydroxylation reaction. Red: Sample taken 
immediately after initiation of the reaction, blue: sample taken after 40 min reaction time, green: sample 
taken after 24 h reaction time. 
The reaction without Sav S112A was performed under identical conditions but leaving 
out the SAV-S112A addition step. The time courses of performing the reaction in the 
presence and absence of Sav S112A are compared in Figure 3.5. If Sav S112A was 
absent from the reaction mixture, accumulation of the product ceased soon after start 
of the reaction yielding less than 5% conversion of the starting material. However, in 
the presence of SAV-S112A, the reaction progressed smoothly to full conversion, 
accumulating the desired product only. 
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Figure 3.5 ― Comparison of the chemoenzymatic hydroxylation of 2-hydroxybiphenyl in the presence 
(blue) and absence (red) of Sav S112A. 
Due to the low solubility of the substrate (2-hydroxy biphenyl) in aqueous reaction 
media, the performance of the catalysts was somewhat limited. Therefore, we 
investigated the cascade reaction in a byphasic system (2LS) wherein a hydrophobic 
organic solvent (e.g. 1-decanol) serves as substrate reservoir and product sink (Figure 
3.6). A typical procedure was: to a buffered solution of NaHCO2 (712 µL, 200 mM in 
NaHCO2, 50 mM in KPi, pH adjusted with NaOH to 7.5) was added [Cp*Ir-biot-p-L)Cl] 
(50 µL of a 1 mM solution in DMF) and either Sav S112A (50 µL, 1 mM free binding 
sites in H2O; 3 free binding sites per tetramer assumed) or H2O (50 µL), respectively. 
The mixture was then supplemented with an FAD solution (10 µL of a 1 mM solution 
in H2O) as well as HbpA stock solution (128 µL, 12.5 mg/mL, 6.9U/mL in KPi buffer, 
pH of buffer 7.5). Immediately afterwards 2-hydroxybiphenyl in 1-decanol (1 mL of a 
100 mM solution) was added. The reaction mixtures were placed in a thermoshaker and 
incubated at 30oC and 800 rpm. After a short mixing period (approx. 1 minute) a sample 
(0.1 mL) was withdrawn and centrifuged to induce phase separation. 10 µL of the 
organic phase were withdrawn (the remaining sample was added back to the reaction 
mixture), diluted with ACN/water (0.99 mL of a 50:50 (v/v) mixture containing 0.1% 
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TFA) and analysed by RP-HPLC as described above. The reaction was subsequently 
initiated by addition of NAD stock solution (50 µL of a 10 mM solution in H2O). 
Samples were taken at the indicated time points (Figure 3.6) and treated as described 
above. For analysis, only the substrate and product concentrations in the organic phase 
were considered. 
 
Figure 3.6 ― Time course of chemoenzymatic hydroxylation of 2-hydroxybiphenyl under biphasic 
(2LPS) conditions in the presence (blue) and absence (red) of Sav S112A. 
Determination of apparent kinetic constants of ATHase catalyzed NAD 
reduction 
Note: the reaction conditions for the kinetic measurement (50 mM KPi-buffer, 200 mM 
NaHCO2) are not identical to the conditions used in the monophasic reaction set-up (42 
mM KPi-buffer, 168 mM NaHCO2).Stock solution: 
 Buffer 1: phosphate buffer 50mM pH 7.5 
 Buffer 2: phosphate/formate buffer (50mM in phosphate, 200mM in NaHCO2 
pH adjusted with NaOH to 7.5) 
 NAD+: 10mM in buffer1 (29.27 mg, purity 90%, contains 10% H2O) was 
dissolved 3.970ml of buffer1. 
 Buffer 3: stock of NAD+ diluted to various concentrations (see Table 3.4).  
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 [Cp*Ir(Biot-p-L)Cl]: stock 1mM (MW 803, weight 2.32mg in 2.889 ml of DMF) 
 ATHase: 10.2 mg of Sav S112A were dissolved in buffer 1 (4.209 mL) and Ir-
stock solution (467µL) were added. This leads to a final concentration of 100 µM 
and a ratio of Ir/free binding sites of 1/3(3 free binding sites per tetramer 
assumed). 
Table 3.4 Volumes and concentrations 
entry volume 
buffer 1 
[µL] 
volume 
buffer 3 
with NAD+  
[µL] 
NAD 
concentration  
of buffer 3 
[µM] 
volume 
ATHase 
[µL] 
volume 
buffer 2 
[µL] 
final conc. 
of NAD+ 
[µM] 
1 450 0 0 50 500 0 
2 250 200 25 50 500 5 
3 250 200 50 50 500 10 
4 250 200 75 50 500 15 
5 250 200 100 50 500 20 
6 250 200 150 50 500 30 
7 250 200 250 50 500 50 
8 250 200 400 50 500 80 
9 250 200 500 50 500 100 
10 250 200 1000 50 500 200 
11 250 200 2000 50 500 400 
12 250 200 4000 50 500 800 
13 250 200 6000 50 500 1200 
14 250 200 8000 50 500 1600 
63 
 
15 250 200 10000 50 500 2000 
 
The sample was prepared in the cuvette (polystyrene) by adding  first  buffer 1 
(prewarmed to 30°C), followed by the ATHase, and then buffer 3 (prewarmed to 30°C). 
The reactions were started by the addition of formate containing buffer 2 (prewarmed 
to 30°C). 
Each measurement was performed in triplicate in a Shimadzu UV-1800 UV 
spectrophotometer (at 30°C) and analysed with UV probe, version 2.34. Absorption was 
detected at 340nm and an absorption coefficient of 6220M-1cm-1 for NADH was used 
for calculation of the kinetic parameters.[50] Rates were determined by considering the 
linear part of increase in absorbance over time. The apparent Michaelis-Menten 
parameters Vmax, Km and  Ki were obtained applying non-linear regression (least 
squares method) using GraphPad Prism 5.0® corresponding to the mMichaelis-Menten 
equation.[51] 
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Figure 3.7 ― Saturation kinetics of ATHase S112A in the reduction of NAD. Errors bars indicate 1 
standard deviation, determined from the triplicate measurement of each rate. 
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4.1 Abstract 
Stereoselectively labelled isotopomers of NAD(P)H are highly relevant for mechanistic 
studies of enzymes which utilize them as redox equivalents. Whereas several methods 
are firmly established for their generation in high diastereomeric purity by enzymatic 
methods, alternative methods have so far not been investigated. This chapter presents 
the stereoselective deuteration of NAD+ at the 4-position (90% de) of the pyridinium-
ring by means of an artificial metalloenzyme. The artificial matalloenzyme consist of a 
biotinylated iridium cofactor embedded in streptavidin isoforms and the resulting 
construct have been previously show to be compatible with natural enzymes. 
Alternative methods for stereoselective NAD(P)+ reduction are expected to be of high 
interest for the mechanistic study of enzyme that accept NAD(P)H mimics and for the 
synthesis of structurally related fine chemicals. 
 
4.2 Introduction 
The coenzymes NAD(P)+ and NAD(P)H play a crucial role in the redox machinery of 
living systems. This relates to their ability to either accept a hydride at the C4-position 
of the pyridine ring in their oxidized form or to donate the respective hydride in the 
reverse-reaction (Scheme 4.1). When the hydride is replaced by a deuteride in the 
reduction step, two diastereoisomers can be formed due to the presence of the 
enantiopure adenine dinucleotide moiety. The diastereoisomers thus differ only in 
their configuration at C4. Stereoselective labelling of the coenzymes with deuterium or 
tritium yields precious mechanistic information for the corresponding enzymes. 
Methods for their preparation in high stereoisomeric purity are well established.[1,2,3]  
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Scheme 4.1  ― Deuteration of NAD+ at the C4 position yields diastereoisomers. 
Biocatalysis gains an ever increasing share in modern chemical manufacture, boosted 
by powerful protein engineering strategies.[4] NAD(P)H or NAD(P)+ mol equivalents are 
required in various biotransformations, including ketoreductases, alcohol 
dehydrogenases, Baeyer-Villiger monooxygenases, imine reductases, and P450s.[5–8] 
These co-substrates are typically regenerated enzymatically in a catalytic concurrent 
fashion.[9] However, alternative approaches employing e.g. chemocatalysis or 
electrochemical reduction have received increasing attention since they offer 
additional flexibility in process conditions and are readily transferrable to NAD(P)-
mimics, which are substantially cheaper than their natural analogues.[10]  
One complex that has been frequently used in non-enzymatic regeneration systems for 
the transfer of reducing equivalents to NAD(P)+ is the achiral [Cp*Rh(bipy)(H2O)]2+.[11] 
At least one report exists where an enantiopure complex was utilized.[12] However, no 
labelling studies were undertaken and accordingly no diastereoselectivity for the 
reduction step studied. We recently reported on the application of an artificial transfer 
hydrogenase (ATHase) for the concurrent regeneration of NADH in a monooxygenase-
coupled reaction.[13] To generate the artificial metalloenzyme, a biotinylated iridium 
pianostool complex was incorporated into streptavidin (Sav) mutant S112A (Figure 4.1). 
The biotinylated ligand for the Cp*Ir moiety is achiral in the vicinity of the metal 
center, and the respective complex has been shown to induce only negligible 
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stereocontrol in the reduction of prochiral imine substrates in the absence of 
streptavidin. However, upon incorporation into Sav, substantial stereocontrol can be 
achieved.[14] Importantly, the concurrent process with the monooxygenase and other 
enzymes was only effective, when the complex was located inside Sav; otherwise 
dramatic deactivation of the monooxygenase and/or the artificial Ir-cofactor 
occurred.[15]    
We have previously shown that substrate reduction with ATHase derived from Sav 
mutants S112A and S112K lead to R- and S- enantiomers for both ketones and imines, 
respectively.[14]  The corresponding X-ray structures of [Cp*Ir-(Biot-p-L)Cl]  S112A[14]  
and [Cp*Ir-(Biot-p-L)Cl]  S112K [15] were recently reported and analysed: for S112A, 
the absolute configuration at [Cp*Ir-(Biot-p-L)Cl] is (S) and for S112K, the absolute 
configuration is (R). Based on modelling studies, we hypothesise that the absolute 
configuration at Ir by-and-large determines the absolute configuration of the alcohol 
and amine products: we term this phenomenon “induced lock-and-key” whereby the 
protein determines which prochiral face of the substrates is reduced.[15] 
Herein we report on the diastereoselectivity of NAD deuteration employing the Ir-
cofactor by itself and upon incorporation into two Sav-mutants (Figure 4.1).  
 
   
Figure 4.1 ― NAD+ reduction, a) with a biotinylated Ir-complex and deuterated sodium formate in the 
absence of streptavidin mutants proceeds with low diastereoselectivity. b) Upon incorporation into 
streptavidin isoforms, the reduction proceeds with high diastereoselectivity. The star symbolizes a 
mutation in streptavidin.  
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4.3 Results and Discussion 
To determine the diastereomeric ratio after reduction with deuteride, 1H-NMR-
spectroscopy offers a convenient means.[16,17] This technique enables the direct 
determination of the diastereoselectivity in the reaction mixture without requiring 
isolation of the products. The only noteworthy differences to potential preparative 
reactions lies in the presence of a small amount of deuterium oxide (5%), the 
dissolution of the biotinylated Ir-complex in DMF-d7 instead of DMF and a short 
centrifugation step. Based on catalysis results obtained in asymmetric imine 
reduction[14] and NADH regeneration[13] with artificial metalloenzymes, the selectivity 
with two representative mutants was investigated. Mutant S112A, employed previously 
for concurrent NADH regeneration, leads to superior enantiomeric excess and high 
turnover numbers in the reduction of 1-methyl-6,7-dimethoxy-3,4-
tetrahydroisoquinoline yielding (R)-configured salsolidine (up to 96% ee).[14] Reduction 
of the same substrate with the AME based on S112K, in contrast, leads to a bias in 
favour of the (S)-enantiomer (up to 78 % ee).[14]  
For the stereoselective NAD+ reduction experiments, deuterated sodium formate was 
used as a deuteride source in the presence of [Cp*Ir(biot-p-L)Cl]S112A and NAD+. 
Following centrifugation, the crude reaction mixtures were analyzed by 1H-NMR 
spectroscopy. While background signals of the protein and other components of the 
crude reaction mixture prevented unambiguous integration of 1D 1H-NMR data, a 
selective one-dimensional TOCSY NMR experiment using irradiation on H6 (5.89 ppm) 
yielded clean spectra with sufficient signal to noise ratio to reliably integrate the two 
resonances attributed to both diastereomers (Figure 4.1). As the TOCSY transfer occurs 
with slightly different efficiency for (4R-2H)-NADH and (4S-2H)-NADH, a calibration 
TOCSY experiment with commercial, non-deuterated NADH was performed (Figure 
4.2a) and the resulting integrals (1.00 : 1.13 for H4S : H4R) were used to normalize the 
integrals of the deuterated species (Figure 4.2b-d). Due to the collapse of the 2JHH 
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coupling constant of 18.1 Hz into a 2JHD of 2.8 Hz, both H4 resonances appear as broad 
singlets in the TOCSY spectrum and the fine structure is lost. The integration yielded a 
de of 87% for mutant S112A and a de of 90% for mutant S112K, while a de of 38% was 
obtained for the sample without Sav (all with an error margin of   1%), after 16 hours 
reaction time (Figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 ― Selected region from selective 1H-TOCSY spectra of a) commercial NADH, and catalytic 
reduction of NAD+ using 2HCOONa with, b) S112A; c) S112K; d) no Sav.  
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The modest but significant diastereoselectivity observed in the absence of Sav arises 
most likely from substrate control considering the formation of basically racemic 
product from achiral starting materials in related transformations.[13,14] Both mutants led 
to a significant improvement in the diastereomeric excess compared to the result 
obtained in the absence of streptavidin (Figure 4.2). Interestingly, for the NAD+ 
reduction, both S112A and S112K ATHases afford the same diastereomer preferentially. 
This observation stands in stark contrast with result previously reported for the ketone 
and imine reduction whereby S112A and S112K afford (R)- and (S)-reduction products 
respectively. In a matched-mismatched spirit, we speculate that the inherent chirality 
of the sugar moiety of NAD+ counterbalances the ATHase preference. This is supported 
by the inherent preference of the substrate in the absence of Sav. Alternatively, one 
NAD+ substrate could bind in the biotin vestibule in S112A, thus modifying the 
environment of the metal complex. Similar results were computed for the imine 
reductase with S112A.[15] The preparation and screening of further mutants might 
provide guiding answer towards the design of ATHases with inverted selectivities for 
the reduction of NAD+. 
 
4.4 Conclusions 
The high chiral induction observed is promising for further applications such as the 
investigation of specificity in enzymes utilizing NAD(P)-mimics and the resulting 
information would be of interest for future enzyme engineering tasks. Furthermore, 
related prochiral structures can be envisaged, namely 3,4 substituted pyridinium ions, 
which would provide valuable building blocks upon asymmetric conversion.[18]  
 
4.5 Experimental part 
Nicotinamide adenine dinucleotide hydrate (NAD+, contains 10% H2O) was purchased 
from Sigma. 2HCOONa was purchased from ABCR. Streptavidin was prepared as 
previously reported.[13] [Cp*Ir(biot-p-L)Cl] was a kind gift from Dr. Marc Dürrenberger 
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and prepared as reported in literature.[19] NMR experiments were performed at 25°C 
(MeOH calibration) on a Bruker Avance III NMR spectrometer operating at 600 MHz 
proton frequency, equipped with a direct detection dual channel, broadband probe-
head with z-gradient. Chemical shifts were referenced against proton solvent peaks 
(4.773 ppm for H2O). The selective TOCSY experiment[20,21] was performed using a 
MLEV17 spinlock sequence with a mixing time of 120 ms, trim pulses of 2.5 ms and a 
selective Gauss shaped refocusing pulse of 80 ms duration.  
Stock solutions: buffer 1: sodium phosphate 50 mM, pH 7.5; buffer 2: 2HCOONa 200 
mM, sodium phosphate 50mM, pH 7.5, {2HCOONa (138 mg) was dissolved in Milli-Q 
H2O (5 ml), sodium phosphate buffer (0.5 ml, 1M) was added and the pH adjusted to 
7.5 by addition of aq. NaH2PO4. Water was added to a total volume of 10 ml}; NAD+ 
stock solution: 10 mM in buffer 1 (NAD+ (29.9 mg, 405 µmol) was dissolved in buffer 1 
(4.05 ml); Ir-stock solution: 10 mM [Cp*Ir(biot-p-L)Cl] (2.55 mg, 3.17 µmol) was 
dissolved in DMF-d7 (317 µl). 
Preparation of ATHase: 
- Sav-mutant S112A (2.53 mg, assuming 3 free binding sites) was dissolved in 
buffer 1 (1.144 mL), and Ir-stock solution was added (11.6 µl).  
- Sav-mutant S112K (2.65 mg assuming 3 free binding sites) was dissolved in 
buffer 1 (1.195 ml), and Ir-stock solution was added (12.1 µl).  
- Sample without SAV mutant (intermediate solutions): buffer 1 (0.495 ml) and 
Ir-stock solution was added (5 µl). Mixing was achieved by means of a vortex 
mixer. 
Reaction set up: To buffer 1 (125 µl) was added buffer 2 (250 µl; final concentration of   
2HCOONa = 100 mM), ATHase (or intermediate solutions) (100 µl, final concentration 
of Ir = 20 µM) and NAD+ stock solution (25 µl, final concentration = 500 µM). 
The reaction was incubated and agitated at 30°C and 200 rpm for 24h by means of a 
Thermomixer (HLC Biotech Model MHR 23). 
Subsequently D2O (50 µl) was added and the NMR spectra recorded. 
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5.1 Abstract 
We report on the optimization of an articial imine reductase based on the biotin-
streptavidin technology. With the aim of rapidly generation chemical diversity, a novel 
strategy for the formation and evaluation of biotinylated complexes is disclosed. 
Tethering the biotin-anchor to the Cp* moiety leaves three free coordination sites on a 
d6 metal for the introduction of chemical diversity by coordination of a variety of 
ligands. To test the concept, 34 bidentate ligands were screened and a selection of the 6 
best was tested in the presence of 21 streptavidin (Sav) mutants for the asymetric imine 
reduction by the resulting three legged piano stool complexes. Enantiopure α-amino 
amides were identified as promising bidentate ligands: up to 63% ee and 190 turnovers 
were obtained in the formation of 1-phenyl-1,2,3,4-tetrahydroisoquinoline with 
[biotinCp*Ir(ʟ-ThrNH2)Cl]SavWT as a catalyst. 
 
5.2 Introduction 
Artificial metalloenzymes result from incorporation of an organometallic catalyst or 
catalyst precursor within a macromolecular scaffold (protein or oligonucleotide).[1–
19]The resulting hybrid catalyst can be optimized by using either genetic or chemical 
methods.[1–8,18–21] In the context of artificial metalloenzymes based on the biotin-
streptavidin technology, we and others have relied on synthesizing various biotinylated 
ligands to provide chemical diversity.[1–4,15,20,21] To generate larger artificial cofactor 
libraries quickly, we reasoned that separating the necessary biotin anchor moiety and 
variable ligand elements would enable us to screen commercially available ligands in 
the presence of streptavidin (Sav; Scheme 5.1). To test the validity of this strategy, we 
selected the asymmetric transfer hydrogenation of prochiral imines catalyzed by 
biotinylated moieties (M = Rh, Ir).  
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Scheme 5.1 ― Artificial metalloenzymes consist of an organometallic catalyst or catalyst precursor 
incorporated within a protein scaffold. The optimization of their catalytic performance is achieved either 
by mutating the protein (green star *) or by varying the bidentate ligand (A—A’). a) The recognition 
element (blue triangle ∆) and the variable bidentate ligand are covalently linked. b) The recognition 
element and the bidentate ligand (A—A’) are distinct and thus allow to screen readily available ligands.  
 
Considering the robustness of the Cp*M moiety,[22,23] we reasoned that for d6 transition 
metals tethering the biotin anchor to the Cp* unit would leave three free coordination 
sites around the metal for further functionalization. It is widely accepted that three-
legged piano stool complex-catalyzed asymmetric transfer hydrogenation proceeds via 
an outer sphere hydride transfer mechanism, which requires only one free 
coordination site around the metal for the reaction to proceed.24–27] This reaction is thus 
ideally suited to test the concept outlined in Scheme 5.1 b.  
 
5.3 Result and Discussion 
The synthesis of the biotinylated catalyst precursors [biotinCp*MCl2]2 (M = Ir, Rh) is 
described elsewhere.[12,19,28,29] The dimeric precursor was reacted in situ with a selection 
of commercially available bidentate ligands (Scheme 5.2). To identify suitable 
coordination conditions, the chiral ligand ʟ-ProNH2 was complexed in situ with the 
dinuclear catalyst precursors [biotinCp*MCl2]2 (M = Ir, Rh) at different pH values 
within the buffer range of 3-(N-morpholino)propanesulfonic acid (MOPS). As the best 
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conversion for the asymmetric transfer hydrogenation of prochiral imine 1a was 
observed at pH 7.8, this value was selected for all subsequent studies.  
A preliminary screen was performed with eight commercially available bidentate 
ligands using [biotinCp*MCl2]2 (M = Ir, Rh) for the reduction of 1-phenyl-3,4-
dihydroisoquinoline 1a with formate as hydride source. The results are presented in 
Table 5.1.  
 
Scheme 5.2 ― Initial selection of bidentate ligands (3-10) for the creation of artificial imine reductases 
based on the biotin-streptavidin technology.  
 
The following trends emerged from these results:  
1. The dinuclear catalyst precursor [biotinCp*IrCl2]2, devoid of any additional 
ligands, demonstrates only low detectable artificial transfer hydrogenases 
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ATHase activity both in the absence and in the presence of Sav, whereas 
[biotinCp*RhCl2]2 displays significant activity only in the absence of Sav (Table 
5.1, entry 1).  
2. Although most ligands tested afford >60 turnovers (>30% yield) if combined 
with [biotinCp*RhCl2]2, only four ligands give rise to >60 turnovers with 
[biotinCp*IrCl2]2. Notably the widely used amino sulfonamide ligand scaffold 
(ligand 9) performs only moderately in comparison to the best ligands under the 
experimental conditions adopted for this screening. With high throughput 
screening in mind, no particular effort was made to improve the performance of 
individual metal-ligand combinations. 
3. Incorporation within Sav leads to a significant decrease in conversion in all but 
two metal-ligand combinations. Both glycine amide 3 and bisoxazoline 10 
combined with [biotinCp*IrCl2]2 afforded more than 180 turnovers for the 
reduction of cyclic imine 1a. Owing to the enantiopure environment provided 
by the Sav host, the corresponding amine 2a is produced in enantioenriched 
form: (S)-2a in 43% ee with 3 and (S)-2a in 14% ee with 10 (Table 5.1, entries 2 
and 9 with [biotinCp*IrCl2]2. 
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Table 5.1 Identification of the most suitable ligand for activating a biotinylated piano stool catalyst 
precursor for the reduction of imine 1a.(a) 
Entry Ligand Yield (ee)(d) [%] 
  Ir(b) Rh(c) 
  No protein Sav-WT No protein Sav-WT 
1 ― 6 (-1) 3 (38) 81 (0) 5 (-5) 
2 3 93 (0) 94 (43) 60 (0) 5 (7) 
3 4 8 (-3) 2 (21) 51 (0) 4 (1) 
4 5 0 (0) 0 (0) 34 (0) 3 (-1) 
5 6 4 (-2) 0 (0) 16 (-1) 3 (-1) 
6 7 31 (0) 13 (16) 35 (-1) 3 (-1) 
7 8 44 (0) 0 (0) 6 (-1) 2 (-6) 
8 9 16 (-1) 6 (13) 36 (0) 3 (1) 
9 10 99 (0) 51 (14) 37 (0) 4 (0) 
(a) The best result are highlighted in boldface. For full experimental details, see the Supporting 
information; (b) Metal catalyst precursor = [biotinCp*IrCl2]2; (c) Metal catalyst precursor= 
[biotinCp*RhCl2]2; (d) A positive ee value refers to the (S) enantiomer; a negative value refers to the (R) 
enantiomer of amine 2a.  
After identifying the α-amino amide scaffold as a promising activating ligands[30–36] in 
the ATHase assembly for the reduction of imine 1a, 28 commercially available amino 
amides were tested in conjunction with [biotinCp*IrCl2]2 in the presence of Sav-WT 
(Figure 5.1 and Table 5.2).  
 
Figure 5.1 ― Selection of amino amide ligands screened for the enantioselective reduction of imine 1a. 
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The following trends emerge from these results: 
1. In the absence of Sav, the enantiopure biotinylated piano stool complexes 
demonstrate up to 29% ee for the reduction of imine 1a. The distant 
enantiopure biotin anchor does not significantly affect the enantioselectivity 
either in the presence of achiral ligands (Table 5.1) or in the presence of mirror-
image amino amides. Accordingly (in the absence of Sav) ʟ-PheNH2 and ᴅ-
PheNH2 afford the amine (S)-2a in 17% ee and (R)-2a in 16% ee respectively 
(Table 5.2, entries 10 and 11). 
2. In most of cases, the transfer hydrogenation activities in the absence and in the 
presence of Sav are comparable. However, incorporation within Sav leads to a 
significant increase in ee value for several combinations (Table 5.2, entries 1, 2, 
4, 6, 8, 12, 18 and 20) or to an inversion of the preferred product enantiomer 
(Table 5.2, entries 5, 7, 9 and 17). In general, incorporation in Sav-WT shifts the 
stereoselectivity in favor of the S enantiomer. 
3. Upon incorporation within Sav, >60% ee of (S)-2a and ≥170 turnovers are 
obtained with either ʟ-LeuNH2, ᴅ-ArgNH2, ʟ-IleNH2 or ʟ-ThrNH2 (Table 5.2, 
entries 6, 9, 18 and 20). The α-amino amides bearing a softer donor side chain 
(e.g. ʟ-MetNH2 and ʟ-HisNH2, Table 5.2, entries 19 and 25) completely inhibit 
catalysis. We hypothesize that the binding mode of these potentially tridentate 
ligands may differ from the other amino amide ligands tested.[34] 
4. The absolute configuration of the amino amide has a modest impact on the 
enantioselectivity of the corresponding artificial metalloenzyme. In the isolated 
cases tested, the Δee value for the matched versus mismatched combinations 
differ by ≤ 20% in the protein (Table 5.2, entries 4 and 5, entries 6 and 7, entries 
8 and 9, entries 10 and 11, entries 16 and 17), except in proline (Δee=75%; 
entries 2 and 3). 
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Table 5.2 Screening of different amino amide ligands for the reduction of imine 1a, employing 
[biotinCp*IrCl2]2 (with or without Sav-WT) as complex precursor.(a) 
Entry Ligand Yield (ee)(b) [%] 
  no protein Sav-WT 
1 GlyNH2 93 (0) 94 (43) 
2 ʟ-ProNH2 99 ( 17) 47 (67) 
3 ᴅ-ProNH2 99 (-29) 28 (-8) 
4 ʟ-ValNH2 99 (20) 70 (63) 
5 ᴅ-ValNH2 99 (-12) 66 (45) 
6 ʟ-LeuNH2 97 (9) 96 (63) 
7 ᴅ-LeuNH2 99 (-13) 96 (51) 
8 ʟ-ArgNH2 98 (7) 71 (52) 
9 ᴅ-ArgNH2 71 (-12) 85 (61) 
10 ʟ-PheNH2 97 (17) 98 (33) 
11 ᴅ-PheNH2 99 (-16) 96 (13) 
12 ʟ-SerNH2 99 (1) 98 (52) 
13 ʟ-GluNH2 99 (11) 94 (30) 
14 ʟ-Pro-NHethyl 83 (13) 5 (44) 
15 ʟ-3,4-dehydro-ProNH2 94 (24) 17 (58) 
16 ʟ-AlaNH2 57 (6) 87 (34) 
17 ᴅ-AlaNH2 56 (-6) 88 (36) 
18 ʟ-IleNH2 98 (5) 89 (65) 
19 ʟ-MetNH2 0 (0) 0 (0) 
20 ʟ-ThrNH2 86 (6) 96 (63) 
21 ʟ-AsnNH2 85 (12) 91 (56) 
22 ʟ-GlnNH2 45 (12) 86 (39) 
23 ʟ-TyrNH2 70 (16) 90 (36) 
24 ʟ-LysNH2 99 (1) 89 (26) 
25 ʟ-HisNH2 0 (0) 0 (0) 
26 ʟ-AspNH2 66 (13) 94 (43) 
27 ʟ-TrpNH2 65 (20) 95 (37) 
28 -GlyNH2 7 (2) 3 (28) 
(a) The best results highlighted in boldface. Reaction conditions: 35 mM substrate, 0.25 mol% 
[biotinCp*IrCl2]2, 0.55 mol% amino amide, 7.4 mg/ml Sav-WT, 0.56M MOPS, 1.4M formate, pH 7.8, 
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incubation for 18 h at 50°C. All listed results are the average of two runs; for full details see the 
supporting information; (b) A positive ee refers to the (S)-enantiomer, whereas a negative ee refers to the 
(R)-enantiomer of amine 2a.  
After identifying promising amino amide ligands, we proceeded to the genetic 
optimization of the ATHase activity. For this purpose, six amino amide ligands (ʟ-
ProNH2, ʟ-ValNH2, ʟ-LeuNH2, ʟ-IleNH2, ʟ-ThrNH2 and GlyNH2) were selected and 
screened in the presence of 21 Sav mutants for the reduction of cyclic imine 1a. The 
corresponding results are presented as a fingerprint in Figure 5.2.  
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Figure 5.2 ― Results of the chemogenetic optimization of ATHases for the asymmetric reduction of 
imine 1a, which are presented in bubble-chart format. The size of the bubbles is proportional to the 
conversion (between 4% and 99%), and the color codes the ee. See Table 5.2 for experimental details. 
The numerical values (conversion, ee) are listed in the Table 5.4.  
 
From the results presented in Figure 5.2, the following conclusions could be drawn: 
1. The best results in terms of enantioselectivity for any ligand are obtained with 
Sav-WT.  
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2. Mutating single residues at position S112 or K121, or mutating both residues 
simultaneously, lead to a decrease in enantioselectivity for all ligands tested. 
The S112Y mutant led, in combination with ʟ-LeuNH2, to an inversion of 
enantioselectivity compared to Sav-WT (63% ee of (S)-2a in Sav-WT and 20% 
ee of (R)-2a in the presence S112Y).  
3. All mutants at position K121 typically lead to high conversions with all amino 
amide ligand tested. In the presence of either ʟ-ProNH2 or ʟ-ValNH2, 
significantly improved conversions compared to Sav-WT were observed with 
mutants K121N, K121A, K121H and K121Y mutants.  
4. In the presence of L124K, L124Y or L124F mutant, a marked decrease in 
enantioselectivity compared with that in the presence of Sav-WT is observed 
for all ligands except ʟ-ProNH2. Conversions were generally good to excellent 
with the L124Y or L124F mutants.  
5. Good to excellent conversions were observed for all double mutant–ligand 
combinations, accompanied by a decrease in enantioselectivity (except ʟ-
ProNH2).  
 
Finally, the substrate scope of the artificial imine reductase was evaluated (Figure 5.3). 
 
 
Figure 5.3 ― Selection of substrates for the asymmetric transfer hydrogenation of cyclic imines. 
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For this purpose, six different prochiral cyclic imines were tested in the presence of 
artificial metalloenzymes [biotinCp*Ir(amino amide)Cl]Sav-WT (amino amide =  
ʟ-ProNH2, ʟ-ValNH2, ʟ-LeuNH2, ʟ-IleNH2, ʟ-ThrNH2, GlyNH2). The results of this 
screening are summarized in Table 5.3.  
 
Table 5.3 Screening of different substrates for the [biotinCp*Ir(amino amide)Cl]Sav-WT mediated 
transfer hydrogenation.  
Entry Ligand Yield (ee) (a) [%] 
  1a 1b 1c 1d 1e 1f 
1 ʟ-ProNH2 47 (67) 99 (5) 100 (6) 69 (-32) 60 (-11) 100 (18) 
2 ʟ-ValNH2 70 (63) 100 (17) 100 (17) 84 (-44) 80 (-22) 86 (16) 
3 ʟ-LeuNH2 96 (63) 100 (3) 100 (18) 95 (-45) 96 (-31) 100 (20) 
4 ʟ-IleNH2 89 (65) 100 (20) 100 (43) 83 (-32) 79 (-22) 10 (18) 
5 ʟ-ThrNH2 96 (63) 100 (25) 100 (41) 98 (-57) 95 (-35) 91 (20) 
6 GlyNH2 94 (43) 100 (4) 100 (18) 96 (-46) 94 (-9) 79 (2) 
(a) A positive value corresponds to the (S)-enantiomer, whereas a negative value corresponds to the (R)-
enantiomer. The absolute configuration of the amines 2d-f was not determined. The best result are 
highlighted in bold face. 
Variation of the substrate led to the following observations and trends: 
1. Conversion of bulky substrate 1a led generally to the highest observed 
enantioselectivites in favor of the (S) product.  
2. Reducing the size of the substituent at position 1 of the dihydroisoquinoline 
moiety from phenyl to methyl resulted in a considerable decrease in 
enantioselectivity.  
3. Introduction of methoxy substituents at position 6 and 7 of the 
dihydroisoquinoline moiety only moderately affected the selectivity.  
4. With 2-substituted 1-pyrrolines, conversions were generally good to excellent. 
5. The highest ee value for 1-pyrrolines was observed for the bulky substrate 
carrying a cyclohexyl substituent in combination with ʟ-ThrNH2. The ee values 
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for the benzyl- and phenyl-substituted substrates 1e and 1f, respectively were 
generally low.  
 
5.4 Conclusion 
To readily access large chemical diversity, a new artificial metalloenzyme design based 
on the biotin-streptavidin technology has been presented. Relying on three-legged 
piano stool complexes and tethering the biotin anchor on the Cp* moiety, allows to 
screen a variety of bidentate ligands for the asymmetric reduction of cyclic imines. An 
initial screen led to the identification of amino amides as versatile bidentate ligands in 
conjunction with the {biotinCp*Ir} moiety. Genetic diversity was introduced by site 
directed mutagenesis. Both chemical diversity and genetic diversity were shown to 
have a significant effect on the activity and the selectivity of the resulting artificial 
metalloenzyme.  
By taking into account the versatility of the {Cp*MLn} moiety in catalysis, we reasoned 
that the strategy disclosed herein will find wide application for the chemical 
optimization of artificial metalloenzymes. Current efforts are aimed at the structural 
and kinetic characterization of such hybrid catalysts.  
 
5.5 Experimental Section 
General procedure for the asymmetric transfer hydrogenation: 
Buffer A (100 l; 0.6M in MOPS in Milli-Q H2O at pH 7.8) was placed in a 
polypropylene (PP) tube, followed by the addition of the biotinylated metal complex 
[biotinCp*MCl2]2 stock solution (3.75 l; 5.0 mM in DMSO) and the ligand stock 
solution (3.75 l, 11 mM in Milli-Q H2O or DMSO, depending on the ligand). The 
mixture was agitated for 30 min at 30°C and 600 rpm in a thermo mixer for 
precomplexation. The corresponding lyophilized Sav mutant (1.6 mg) was dissolved in 
buffer B (100 μl, 0.6M in MOPS, 3.0M in HCO2Na in Milli-Q H2O at pH 7.8). Then, 
Sav-mixture (100 l) was added to the PP tube containing the metal complex and 
agitation was continued for 15 min at 30°C and 600 rpm, to ensure binding of the 
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biotinylated complex to Sav. Finally the substrate stock solution was added (7.5 l; 1M 
in DMSO) and the mixture was agitated at 50°C for 18 h. Subsequently, NaOH(aq) (60 µl 
5M solution) was added to the reaction mixture, followed by addition of CH2Cl2 (1 ml). 
The phases were mixed thoroughly with a vortex mixer. The organic phase was 
separated through pipetting and transferred to another PP tube, which contained 
anhydrous Na2SO4. Solids were separated by centrifugation (2 min. at 21’100 g) and the 
supernatant analyzed by using HPLC or GC.  
 
5.5 Supporting Information 
General information 
All amino acid amide ligands were purchased in their free form (H-ʟ-ProNH2, H-ᴅ-
ProNH2, H-ʟ-PheNH2, H-ᴅ-PheNH2, H-ʟ-GluNH2, H-ʟ-AspNH2, H-ʟ-LeuNH2, H-ᴅ-
LeuNH2) or as their hydrochloride salts (H-ʟ-ValNH2·HCl, H-ᴅ-ValNH2·HCl, H-ʟ-
ArgNH2·HCl, H-ʟ-ArgNH2·HCl, H-ʟ-SerNH2·HCl, H-ʟ-ProNHEt·HCl, H-ʟ-3,4-
dehydro-ProNH2·HCl, H-ʟ-AlaNH2·HCl, H-ᴅ-AlaNH2·HCl, H-ʟ-IleNH2·HCl, H-ʟ-
MetNH2·HCl, H-ʟ-ThrNH2·HCl, H-ʟ-AsnNH2·HCl, H-ʟ-GlnNH2·HCl, H-ʟ-
TyrNH2·HCl, H-ʟ-LysNH2·HCl, H-ʟ-HisNH2·HCl, H-ʟ-TrpNH2·HCl) from Bachem and 
used as received. H-GlyNH2.HCl was purchased from Fluka. All other bidentate ligands 
were purchased from Aldrich, Acros and TCI. 3-(N-morpholino)propanesulfonic acid 
(MOPS) was purchased from Alfa Aesar. 1-methyl-3,4-dihydroisquinoline 
hydrochloride hydrate was purchased from Acros. Racemic standards were prepared by 
reduction of the corresponding imine or the hydrochloric salt thereof with NaBH4 in 
methanol.  
Streptavidin (Sav) mutants were expressed, purified and characterized as previously 
described.[37] The synthesis of the biotinylated complexes [biotinCp*IrCl2]2 and 
[biotinCp*RhCl2]2 is described elsewhere.[19] Substrate 1a, 1d, 1e and 1f (Scheme 5.3) 
were synthesized according to literature procedures. [38,39]  
Reaction mixtures were agitated with a thermo mixer (HLC Biotech Model MHR 23). 
HPLC measurements were performed on Agilent (or hp) machines equipped with 
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modules from the 1100 and 1200 series and diode array detectors (if not indicated 
otherwise). HPLC columns were used with the appropriate guard columns. Column 
and conditions are indicated for each compound separately. GC measurements were 
performed on Agilent GCs of the 6890 series equipped with FIDs. 
 
Preparation of stock solutions 
Reaction buffer A was prepared by dissolving MOPS (final conc. 0.6 M) in Milli-Q 
H2O; the pH was adjusted to 7.8 with aq. 10N NaOH. Reaction buffer B was prepared 
by dissolving MOPS (final conc.0.6 M), NaHCO2 (final conc. 3.0 M) in Milli-Q H2O; 
the pH was adjusted to 7.8 with 10N aq. NaOH. The [biotinCp*IrCl2]2 and 
[biotinCp*RhCl2]2 stock solutions (5.0 mM) were prepared by dissolving the complexes 
in appropriate amounts of DMSO. The ligand stock solutions (11 mM) of the amino 
amides H-ʟ-ProNH2, H-ᴅ-ProNH2, H-ʟ-LeuNH2, H-ᴅ-LeuNH2, H-ʟ-PheNH2, H-ᴅ-
PheNH2 and β-GlyNH2 were prepared by dissolving these compounds in DMSO. All 
other amino amides were dissolved in Milli-Q H2O. All non-amino acid amide ligands 
were dissolved in DMSO to a final concentration of 11 mM. The substrate stock 
solutions were prepared by placing the corresponding substrate in a volumetric flask (1 
ml), followed by addition of DMSO to a final concentration of 1 M.  
 
General procedure for the asymmetric transfer hydrogenation 
Complexation:  
Buffer A (100 l) was placed in a 1.5 ml PP-tube, followed by addition of the 
biotinylated metal complex stock solution (3.75 l) and the ligand stock solution (3.75 
l). The mixture was agitated for 30 min at 30°C and 600 rpm in a thermo mixer to 
allow the formation of the complex.  
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Preparation of ATHase:  
The corresponding lyophilized Sav-mutant (1.6 mg for 100 l buffer; final 
concentration in the reaction = 7.4 mg/ml) was dissolved in buffer B (note: three free 
binding sites (fbs) per tetramer were assumed to ensure the presence of sufficient fbs; 
the actual number of fbs is usually higher).  
 
After complexation, 100 l of the prepared ATHase solution were added to the former 
PP-tube (containing the prepared metal complex), and agitation was continued for 15 
min at 30°C and 600 rpm (to allow the binding of the biotinylated complex to Sav). 
Finally the substrate stock solution was added (7.5 l; final concentration in the 
reaction = 35 mM) and the mixture was agitated at 50°C for 18 h. Subsequently aq. 
NaOH (60 µl of a 5 M solution) was added to the reaction mixture followed by addition 
of CH2Cl2 (1 ml).  
The phases were thoroughly mixed by means of a Vortex mixer. The organic phase was 
separated by pipetting and transferred to another PP-tube, which contained anhydrous 
Na2SO4. Solids were separated by centrifugation (2 min at 21’100 g) and the supernatant 
analyzed by HPLC or GC.  
 
Substrates 1a and 1b:  
Chiral stationary phase HPLC (chiralpak IC 250  4.6 mm, 5 m; hexane/i-
PrOH/HNEt2 97:3:0.06, 1 ml/min, 25°C, detection at 265 nm). Conversion of substrate 
1a: Tret = 7.6 min ((S)-2a), Tret = 10.5 min ((R)-2a), Tret = 16.0 min (starting material 1a). 
Conversion of substrate 1b: Tret = 10.6 min ((S)-2b), Tret = 11.4 min ((R)-2b), Tret = 17.9 
min (starting material 1b). The absolute configuration of amine 2a was assigned by 
comparison with a commercial sample of (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline 
(Fluorochem). The absolute configuration of amine 2b was assigned by comparison 
with literature data.[40] Conversions for substrates 1a and 1b were determined by 
comparison of the signal area of product and substrate peaks under consideration of the 
experimentally determined response factors.  
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Substrate 1c:  
Chiral stationary phase HPLC (chiralpak IC 250  4.6 mm, 5 m; CH2Cl2/i-
PrOH/HNEt2 98:2:0.1, 1 ml/min, 25°C, detection at 265 nm). Conversion of substrate 
1c: Tret = 5.6 min ((S)-2c), Tret = 6.1 min ((R)-2c), Tret = 7.8 min (starting material 1c). 
The absolute configuration of amine 2c was assigned by comparison with literature 
data.[20] Conversions for substrate 1c were determined by comparison of the signal area 
of product and substrate peaks under consideration of the experimentally determined 
response factors.  
 
Substrates 1d-f:  
For substrates 1d, 1e and 1f the conversion was determined by GC-FID (Agilent J&W 
CAM, 30 m × 0.32 mm, 0.25 µm; 150  C isothermal, 1.7 ml He/min; injector: 250°C, 
split 100; detector: 240°C). Conversion of substrate 1d: Tret = 3.6 min (amine 2d), Tret = 
3.3 min (imine 1d). Conversion of substrate 1e: Tret = 7.72 min (amine 2e), Tret = 8.7 min 
(imine 1e). Conversion of substrate 1f: Tret = 6.4 min (amine 2f), Tret = 9.2 min (imine 
1f). For ee-determination, products 2d, 2e and 2f were converted to their 
corresponding trifluoroacetamides. Trifluoroacetic anhydride (TFAA, 200 µl) was 
added to the GC-samples used for conversion determination and volatiles were 
removed to near dryness in a gentle stream of N2. The residue was dissolved in a small 
amount of CH2Cl2 (30-100 l) and analyzed by GC-FID on a chiral stationary phase 
(Agilent CP-Chirasil-DEX CB, 25 m × 0.25 mm, 0.25 µm; 140°C isothermal, 1.7 ml 
He/min; injector: 300°C, split 100; detector: 275°C). Product 2d: T1 = 9.6 min, T2 = 9.9 
min; Product 2e: T1 = 10.7 min, T2 = 11.0 min; Product 2f: T1 = 16.4 min, T2 = 17.0 min. 
The absolute configuration of products 2d-f was not determined.  
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Scheme 5.3 ― List of all substrates screened and the corresponding reduced products (standard 
conditions).  
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Table 5.4 Results of the chemogenetic optimization of ATHase for the asymmetric reduction of imine 
1a.(a) 
entry mutant 
ʟ-ProNH2 ʟ-ValNH2 ʟ-LeuNH2 ʟ-IleNH2 ʟ-ThrNH2 GlyNH2 
conv 
[%] 
ee(b) 
[%] 
conv 
[%] 
ee(b) 
[%] 
conv 
[%] 
ee(b) 
[%] 
conv 
[%] 
ee(b) 
[%] 
conv 
[%] 
ee(b) 
[%] 
conv 
[%] 
ee(b) 
[%] 
1 Sav-WT 47 67 70 63 96 63 89 65 96 63 94 43 
2 S112F 41 60 47 28 96 14 54 33 96 23 34 10 
3 S112Y 28 46 24 -3 68 -20 34 -7 69 -6 48 -7 
4 S112R 9 45 8 20 14 21 9 20 13 31 8 11 
5 S112T 29 58 32 22 91 26 31 30 86 29 93 25 
6 S112L 21 50 27 14 52 -6 25 13 52 11 40 -7 
7 S112D 21 50 27 14 52 -6 25 13 52 11 40 -7 
8 S112A 27 57 52 30 84 36 53 35 97 54 89 13 
9 S112G 26 54 34 16 46 33 23 24 55 39 30 22 
10 K121N 97 60 97 15 99 25 99 30 98 41 99 14 
11 K121A 86 58 97 25 99 39 97 29 97 40 98 15 
12 K121H 95 59 97 22 99 38 98 34 97 34 98 11 
13 K121Y 97 59 89 13 98 25 89 20 94 31 42 13 
14 K121R 44 61 72 27 96 40 82 36 93 51 76 17 
15 L124K 26 53 13 15 13 21 10 17 9 21 10 0 
16 L124Y 53 45 75 8 95 -3 59 3 87 9 58 -10 
17 L124F 70 58 91 7 98 4 94 4 97 15 97 -5 
18 L124V 50 52 32 13 67 16 38 20 50 13 48 -6 
19 S112G-N118T 42 60 79 18 97 27 91 27 97 49 97 18 
20 S112A-K121N 61 53 95 22 98 25 97 29 99 25 97 -2 
21 S112A-K121A 68 59 95 23 97 35 95 28 97 35 95 1 
(a) See Table 5.2 for experimental details. (b) A positive value corresponds to the (S)-enantiomer, 
whereas a negative value corresponds to the (R)-enantiomer of amine 2a.  
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Chapter 6 
_________________________ 
Conclusion and outlook  
The subject of this work was the creation of artificial metalloenzymes as a promising 
approach to combine the favourable aspects of biocatalysis and homogeneous catalysis. 
Based on the biotin/(strept)avidin technology and Cp*Ir and Cp*Rh derived 
organometallic moieties, ATHases (Artificial Transfer Hydrogenases) were generated. 
With the ultimate goal of performing efficient in vivo catalysis, potential interactions 
between the catalyst and the biological environment were considered. 
Biotransformation often requires cofactor regeneration, which is performed by a 
second enzyme. The development of alternative non-enzymatic NADH regeneration 
methods is still an active field of research. In the chemical method for NADH 
regeneration, the mutual inhibition between the organometallic catalyst and the 
natural enzymes is a common issue. We observed that [Cp*Ir(biot-p-L)Cl] is a better 
catalyst (TOF 4.6 min-1) compared to [Cp*Rh(bipy)H2O]2+ (TOF 0.27 min-1) in terms of 
activity for NADH regeneration. To overcome the mutual inhibition challenge, we 
incorporated the organometallic catalyst [Cp*Ir(biot-p-L)Cl] into streptavidin (Sav) to 
create an artificial transfer hydrogenase (ATHase). 
The resulting ATHase showed a TOF higher than [Cp*Rh(bipy)H2O]2+, and was 
successfully coupled with HbpA to convert 2-phenylphenol to phenylcatechol. Only 
the desired product was generated in the presence of Sav, while in the absence of Sav-
shielding, less than 5% of product was formed. The presence of Sav efficiently shielded 
the iridium complex from interaction with HbpA and subsequent mutual inhibition, 
demonstrating the applicability of concurrent cascade reactions. The concurrent 
reaction could also be carried out under biphasic conditions, illustrating the versatility 
of the ATHase in terms of reaction conditions.  
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Further studies should address the optimization of the ratio ATHase/HbpA to improve 
the reaction rates, as well as the dependence of the NADH regeneration system on the 
formate concentration. The immobilization of the entire enzyme cascade or the 
coupling of the ATHase for NADH regeneration with different redox NADH 
dependent enzymes should be investigated to demonstrate the general applicability of 
the regeneration system.  
The diastereoselectivity of NAD+-reduction at the C4-position was also investigated. In 
the absence of Sav, 38% d.e. was observed, due to substrate control (NAD+). However 
in the presence of mutants S112K and S112A, diastereomeric excesses of 90% and 87%, 
respectively, were obtained for the (R)-diastereomer. Additional work should be 
carried out to design and identify mutants, which will provide the opposite enantiomer 
for the reduction of NAD+, and allow to gain mechanistic information for the 
corresponding ATHase. 
The scope and potential of ATHases were investigated further. Taking into account the 
stability of three legged piano stool complexes based on IrCp* and RhCp*, the biotin 
anchor was tethered to the Cp* moiety, leaving three free coordination sites for 
screening various bidentate ligands. This methodology enabled the rapid generation of 
a large library of artificial cofactors, and led to the identification of α-amino amides as 
functional bidentate ligands in combination with the [biotinCp*IrCl2]2 for transfer 
hydrogenation. A range of 28 commercial available α-amino amides was screened, and 
the best six were combined with 21 streptavidin variants. Up to 63% ee and 96% yield 
(190 TON) were obtained in the presence of [biotinCp*Ir(ʟ-ThrNH2)CL]SavWT. 
These findings demonstrate that both chemical- and genetic diversity have significant 
effect on the activity and selectivity in the reduction of cyclic imines. Screening of a 
wider library of mutants will aim to improve the selectivity of the reaction, and the 
characterization of this novel hybrid catalyst will allow a better understanding of its 
mechanism. 
These studies revealed the potential and versatility of the created artificial transfer 
hydrogenases for different reactions in terms of activity and selectivity. Further 
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investigation will aim at structural, mechanistic and kinetic characterization of the 
created ATHases to better understand their operational mode, and expand their 
application by combining them with natural enzymes for biotechnological purposes. 
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